PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 1, OPEN-LABEL, TWO-PART STUDY TO EVALUATE THE EFFECT OF 
TWO STEADY-STATE DOSE LEVELS OF PF-06882961 ON THE 
PHARMACOKINETICS OF SINGLE ORAL DOSES OF ATORVASTATIN AND
MIDAZOLAM IN HEALTHY ADULTS AND AN ORAL CONTRACEPTIVE IN 
HEALTHY POST-MENOPAUSAL FEMALES
Study Intervention Number: PF-06882961
Study Intervention Name: N/A
US IND Number:EudraCT Number: N/A
ClinicalTrials.gov ID:  N/A
Protocol Number: C3421047
Phase: 1
Brief Title: A Phase 1, 2-Part Study to Evaluate the Effect of 2 Steady-State Doses of 
PF-06882961 on Single-Dose Atorvastatin, Midazolam and Oral Contraceptive Pharmacokinetics in Healthy Adult Participants.
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.
CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Original Protocol 30August 2021

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................13
1.3. Schedule of Activities .............................................................................................13
2. INTRODUCTION ...............................................................................................................30
2.1. Study  Rationa le.......................................................................................................30
2.2. Background .............................................................................................................30
2.2.1. Nonclinical Pharmacology ..........................................................................31
2.2.2. Nonclinical Pharmacokinetics and Metabolism
.........................................31
2.2.3. Nonclinical Safet y
......................................................................................32
2.2.4. Clinical Overview and Safet y
.....................................................................33
2.2.4.1. Clinical Pharmacokinetics .........................................................34
2.3. Benefit/Risk Assessment
.........................................................................................35
2.3.1. Risk Assessment .........................................................................................36
2.3.2. Benefit Assessment .....................................................................................38
2.3.3. Overall Benefit/Risk Conclusion ................................................................39
3. OBJECTI
VES AND EN DPOINTS .....................................................................................39
4. STU DY DESIGN .................................................................................................................40
4.1. Overall Design .........................................................................................................40
4.1.1. Part A
..........................................................................................................41
4.1.2. Part B
..........................................................................................................41
4.2. Scientific Rationale for Study  Design .....................................................................42
4.2.1. Part A
..........................................................................................................42
4.2.1.1. Midazolam Administration
.......................................................42
4.2.1.2. Atorvastatin Administration ......................................................43
4.2.1.3. PF -06882961 Administration ....................................................44
4.2.2. Part B
..........................................................................................................45
4.2.2.1. Oral Contraceptive Administration
...........................................45
4.2.2.2. PF -06882961 Administration ....................................................45

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 44.2.3. Parts A and B Safety Assessments .............................................................46
4.2.4. Diversity of St udy Popul ation ....................................................................46
4.2.5. Choice of Contraception/Barrier Requirements .........................................47
4.3. Justification for Dose ..............................................................................................47
4.4. End of Study Definition ..........................................................................................48
5. STUDY POPULATION ......................................................................................................49
5.1. Inclusion Criteria.....................................................................................................49
5.2. Exclusion Criteria....................................................................................................505.3. Lifestyle Cons iderations..........................................................................................53
5.3.1. Meals and Dietary Restrictions...................................................................535.3.2. Caffeine, Alcohol, and Tobacco .................................................................545.3.3. Activity .......................................................................................................545.3.4. Contraception..............................................................................................55
5.4. Screen Failures ........................................................................................................55
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY .................................55
6.1. Study Intervention(s) Administered ........................................................................56
6.1.1. Administration ............................................................................................56
6.2. Preparation, Handling, Storage, and Accountability...............................................57
6.2.1. Preparation and Dispensing ........................................................................58
6.3. Measures to Minimize Bias: Randomization and Blinding.....................................59
6.3.1. Allocation to Study Intervention ................................................................59
6.4. Study Intervention Compliance...............................................................................616.5. Dose Modification...................................................................................................616.6. Continued Access to Study Intervention After the End of the Study......................616.7. Treatment of Overdose............................................................................................616.8. Concomitant Therapy..............................................................................................62
6.8.1. Rescue Medicine.........................................................................................63
6.8.1.1. Management of Nausea and Vomiting......................................63
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL...........................................................................63
7.1. Discontinuation of Study Intervention ....................................................................63CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 57.2. Participant Discontinuation/Withdrawal From the Study .......................................64
7.2.1. Withdrawal of Consent ...............................................................................65
7.3. L ost to Follow up
....................................................................................................65
8. STUDY A SSESSMENTS AND PROCE DURES ...............................................................65
8.1. Efficacy  Assessments ..............................................................................................66
8.2. Safet y Assessments .................................................................................................66
8.2.1. Phy sical Examinations ................................................................................67
8.2.2. Vital Signs ..................................................................................................68
8.2.2.1. Temperature ..............................................................................68
8.2.3. Electrocardiograms
.....................................................................................68
8.2.4. C linical Safety  Laboratory  Assessments ....................................................69
8.2.5. COVID -
19 Specific Assessments...............................................................70
8.2.6. Management of Hy pogly cemia ...................................................................70
8.2.6.1. Definition and Severit y of Categorization of 
Hypoglycemic Adverse Event (HAE) ................................ ............... 70
8.2.7. Glucometer Monitoring of Glucose............................................................71
8.2.8. Pregnancy  Testing ......................................................................................72
8.2.9. Suicidal I deation and Behavior Risk Monitoring .......................................72
8.2.9.1. Columbia Suicide Severit y Rating Scale (C -SSRS) .................72
8.2.9.2. Patient Health Questionnaire
-9 (PHQ -9) ..................................73
8.2.9.3. Referral to a  MHP
....................................................................73
8.3. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................73
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......74
8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................75
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF ...................75
8.3.2. Method of Detecting AEs and SAEs ..........................................................75
8.3.3. Follow -Up of AEs and SAEs ......................................................................75
8.3.4. Regulatory
 Reporting Requirements for SAEs ................................ ........... 75
8.3.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and O ccupational Exposure .....................................................76
8.3.5.1. Exposure During Pregnancy ......................................................76
8.3.5.2. Exposure During Breastfeeding ................................................78

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 68.3.5.3. Occupational Exposure .............................................................78
8.3.6. Cardiovascular and Death Events...............................................................788.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................78
8.3.8. Adverse Events of Special Interest.............................................................78
8.3.8.1. Lack of Efficacy........................................................................78
8.3.9. Medical Device Deficiencies......................................................................798.3.10. Medication Errors .....................................................................................79
8.4. Pharmacokinetics ....................................................................................................79
8.4.1. PK of Atorvastatin and Ortho-hydroxyatorvastatin....................................808.4.2. PK of Midazolam and 1-OH-Midazolam ...................................................818.4.3. PK of Levonorgestrel..................................................................................818.4.4. PK of Ethinyl Estradiol...............................................................................818.4.5. PK of PF-06882961 ....................................................................................82
8.6.5. Plasma for Analysis of 4- β-hydroxycholesterol/cholesterol (Part A 
only) .................................................................................................................83
8.7. Immunogenicity Assessments .................................................................................838.8. Health Economics ...................................................................................................83
9. STATISTICAL C ONSIDERATIONS ................................................................................83
9.1. Statistical Hypotheses .............................................................................................849.2. Analysis Sets ...........................................................................................................849.3. Statistical Analyses .................................................................................................84
9.3.1. General Considerations...............................................................................84
9.3.1.1. Derivation of Pharmacokinetic Parameters...............................84CCI
CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 79.3.2. Statistical Methods for Pharmacokinetic Data ...........................................86
9.3.3. Other Safet y Analyses ................................................................................87
9.3.3.1. Electrocardiogram Analy ses......................................................88
9.3.4. Other Anal yse(s).........................................................................................88
9.4. Interim Anal yses.....................................................................................................88
9.5. Sample Size Determination .....................................................................................88
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................91
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............91
10.1.1. Regulatory and Ethical Considerations ....................................................91
10.1.1.1. Reporting of Safety  Issues and Ser ious Breaches of the 
Protocol or I CH GCP .........................................................................91
10.1.2. Financial Disclosure .................................................................................92
10.1.3. I nformed Consent Process ................................ ................................ ........ 92
10.1.4. Data Protection .........................................................................................93
10.1.5. Committees Structure ...............................................................................93
10.1.5.1. Data Monitoring Committee ...................................................93
10.1.6. Dissemination of Clinical Study  Data ......................................................93
10.1.7. Data Qualit y Assurance ............................................................................95
10.1.8. Source Documents ....................................................................................96
10.1.9. Study  and Site Start and Closure ..............................................................96
10.1.10. Publication Policy ...................................................................................97
10.1.11. Sponsor’s Qualified Medical Personnel .................................................98
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................99
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting ...................................................................101
10.3.1. Definition of AE .....................................................................................101
10.3.2. Definition of an SAE ..............................................................................102
10.3.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ..........................................................................104
10.3.4. Reporting of SAEs
..................................................................................107
10.4. Appendix 4: Contraceptive and Barrier Guidance ..............................................108
10.4.1. Male
........................................................................................................108

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 810.4.2. Female Participant Reproductive Inclusion Criteria...............................108
10.4.3. Woman of Childbearing Potential ..........................................................10910.4.4. Contraception Methods...........................................................................109
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .....112
10.7. Appendix 7: ECG Findings of Potential Clinical Concern .................................11410.8. Appendix 9: Abbreviations .................................................................................116
11. REFERENCES ................................................................................................................1 20
LIST OF TABLES
Table 1. Part A - Overall Schedule of Activities Screening to Period 5.................15Table 2. Schedule of Activities – Day 1 of Period 1 (Atorvastatin ONLY), 
Period 4 (Atorvastatin + PF-06882961 120 mg BID), and Period 7 (Atorvastatin + PF-06882961 200 mg BID).............................................20
Table 3. Schedule of Activities – Day 1 of Period 2 (Midazolam ONLY), 
Period 5 (Midazolam + PF-06882961 120 mg BID) and Period 8 (Midazolam + PF-06882961 200 mg BID) ..............................................21
Table 4. Schedule of Activities – Day 31 of Period 3 and Day 19 of Period 6 
(PF-06882961 only)..................................................................................22
Table 5. Part B - Overall Schedule of Activities through Period 5 ........................23Table 6. Schedule of Activities – Day 1 of Period 1 (OC ONLY), Period 3 
(OC + PF-06882961 120 mg BID) and Period 5 (OC + PF 06882961 200 mg BID) ............................................................................28
Table 7. Schedule of Activities – Day 31 of Period 2 and Day 19 of Period 4 
(PF-06882961 only)..................................................................................29
Table 8. Part A Dosing ...........................................................................................56Table 9. Part B Dosing............................................................................................57Table 10. PF-06882961 Dosing Regimens Part A....................................................60Table 11. Plasma PK Parameters for Ator vastatin, Ortho- hydroxyatorv astatin, 
Midazolam, 1-OH-Midazolam, Levonorgestrel and Ethinyl Estradiol....................................................................................................85
Table 12. Plasma PK Parameters for PF-06882961 .................................................86
Table 13. Expected Widths of the 90% CIs (with 80% Coverage Probability) 
for Different Possible Estimated Effects and Parameters of Interest .......90
Table 14. Protocol-Required Safety Laboratory Assessments .................................99CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title: A Phase 1, 2-Part Study  to Evaluate t he Effect of 2Stead y - State Doses of 
PF-06882961 on Single -Dose Atorvastatin , Midazolam and Oral Contraceptive 
Pharmacokinetics i
n Healthy Adult Participants.
Rationale
This is a 
Phase 1, open- label , 2-partstudy  to evaluate the effect of 2stead y-state dose levels 
of PF -06882961 on the SD pharmacokinetics of 1) atorvastatin andmidazolam in healthy  
adult male and female participants (Part A) ,and 2) an OC in health yPMfemale participants 
(Part B) .  The intent of this study  is to generate safety , tolerability , and pharmacokinetic data 
for further clinical development.
Objectives and Endpoints
Objectives Endpoints
Part A
Prim ary: Prim ary: 
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of atorvastatin in healthy male 
and female adult participants. 
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of midazolam in healthy male 
and female adult participants. Atorvastatin plasma pharmacokinetic 
parameters: AUC inf(if data permit *otherwise 
AUC last) in Periods 1, 4 and 7.
Midazolam plasma pharmacokinetic parameters: 
AUC inf(if data permit *otherwise AUC last) in 
Periods 2, 5 and 8.
Secondary: Secondary: 
To evaluate the safety and tolerability of 
PF-06882961 administered separately and in 
combination with atorvastatin or midazolam in 
healthy male and female adult participants.Assessment of TEAEs , clinical laboratory 
abnormal ities, vital signs, body weight, and 
ECG parameters during Part A of the study .
Assessment of mental health as determined by 
C-SSRS and PHQ -9during Part A of the study.
Tertiary/Exploratory: Tertiary/Exploratory: 
To evaluate the effects of PF -06882961 on 
additional pharmacokinetic parameters of 
atorvastatin and midazolam in healthy male and 
female adult participants.Additional plasma pharmacokinetic parameters 
for atorvastatin (Periods 1, 4 and 7) and 
midazolam (Periods 2, 5 and 8): C maxand Tmax; 
andCL/F, V z/F, t ½, as data permit .
To evaluate the MDpharmacokinetics of 
PF-06882961 in healthy male and female adult 
participants.PF-06882961 plasma pharmacokinetic 
parameters at Days 35 and 58: AUC 24, Cmax, 
Tmax.
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of ortho -hydroxy atorvastatin 
in healthy male and female adult participants. Ortho -hydroxyatorvastatin plasma 
pharmacokinetic parameters: AUC last, Cmax, Tmax;
and AUC infandt½as data permit in Periods 1, 
4and 7. Metabolite/parent 
(ortho -hydroxyatorvastatin/atorvastatin )ratios 
will also be calculated. 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 10To evaluate the effects of PF -06882961 on the 
pharmacokinetics of 1-OH-midazolam in 
healthy male and female adult participants.
To evaluate the effects of PF -06882961 on 
biomarkers of CYP3A induction. [Optional ].1-OH-midazolam plasma pharmacokinetic 
parameters : AUC last, Cmax, Tmax; and AUC infand 
t½as data permit in Periods 2, 5 and 8.   
Metabolite/parent 
(1-OH-midazolam /midazolam ) ratios will also 
be calculated.
Morning predose 
4-β-hydroxycholesterol/cholesterol plasma ratio 
on Day 1 in Periods 2, 5, and 8.  Morning 
predose plasma -derived EVon Day 1 in 
Periods 2, 5, and 8.
Part B
Prim ary: Prim ary: 
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of an OC(LE/EE) in healthy
PMfemale participants.LEplasma pharmacokinetic parameters: AUC inf
(if data permit *otherwise AUC last) in Periods 1, 
3 and 5.
EEplasma pharmacokinetic par ameters: AUC inf
(if data permit *otherwise AUC last) in Periods 1, 
3 and 5.
Secondary: Secondary: 
To evaluate the safety and tolerability of 
PF-06882961 administered separately and in 
combination with an OC(LE/EE) in healthy 
PMfemale participants.Assessment of TEAEs , clinical laboratory 
abnormalities, vital signs, body weight, and 
ECG parameters during Part B of the study .
Assessment of mental health as determined by 
C-SSRS and PHQ -9during Part B of the study .
Tertiary/Exploratory: Tertiary/Exploratory: 
To evaluate the effects of PF -06882961 on 
additional pharmacokinetic parameters of an OC
(LE/EE ), administered separately, in healthy PM
female participants.
To evaluate the pharmacokinetics of multiple 
doses of PF -06882961 in healthy PMfemale 
participants.Additional plasm apharm acokinetic parameters 
for LE and EE (both in Periods 1, 3 and 5): 
Cmax, Tmax; and CL/F, Vz/F, t ½as data permit.
PF-06882961 plasma pharmacokinetic 
parameters at Days 3 6and 60: AUC 24, Cmax, 
Tmax.
* Should it be deemed that too few AUC infestimates (eg, less than 12 for a single treatment) are obtained 
from the evaluable participants, AUC lastmay be selected as the primary endpoint for CSR reporting.  This 
will be considered for the atorvastatin , midazolam ,LE,andEEobjectives separately.
Overall Design
Brief Summary
This study is a Phase 1, open-label, stud y that will be conducted in 2parts. Part A is an 
open -label, 8-period, fixed -sequence design to evaluate the effect of 2steady -state dose 
levels of PF -06882961 on the SD pharmacokinetics of atorvastatin and midazolam, 
administered separatel y, in healthy adult male and female partici pants .Part B is an 
open -label, 5-period, fixed -sequence design to evaluat ethe effect of 2steady -state dose 
levels of PF -06882961 on the PK of an OCin healthy  PMfemale participants (Part B).  

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 11Participants will participate in either Part A or Part B (not both), and Parts A and B are 
expected to be conducted in parallel, if possible. For participants in either Part A or Part B, 
the total duration of participation from the Screening Visit to the FUcontact will be 
approximately 18weeks.
Number of Participants
A sample 
size of approximately  16 participants in Part A and 16participants in Part B will be 
enrolled such that approximately  12evaluable participants complete each Part of the study .  
This number of evaluable participants has bee n selected to provide sufficient precision to 
detect a 1.25- fold difference in AUC inffor either atorvastatin ,midazolam, LE, or EE.
Potential participants who are screened for the purpose of determining eligibility  for the 
study , but do not participate i n the study , are not considered enrolled, unless otherwise 
specified b y the protocol.
Note: "Enrolled" means a participant's agreement to participate in a clinical study  following 
completion of the informed consent process and screening . A participant wil l be considered 
enrolled if the informed consent is not withdrawn prior to participating in any  study  activity  
after screening . 
Intervention Groups and Duration
For the purposes of this protocol, study  intervention refers to PF -06882961.  
The purpose of 
this study is to characterize the effect of PF -06882961, administered at 
2steady -state dose levels, on the PK of single doses of atorvastatin (20mg)or midazolam 
(
5mg), administered separately, in healthy  adult male and female participants (Part A), or an
OC(LE 0.15 mg/ EE0.03 mg)in healthy  PM female participants (Part B) .  Titration of 
PF-06882961 doses will be utilized to achieve doses of 120 mg BID and 200 mg BID in 
PartA Table 8and Part BTable 9. The drug -drug interaction effect will be initially  assessed 
at PF -
06882961 120 mgBID and again at 200 mg BID , as these doses are being studied in 
Phase 2 for T2DM and Obesity . 
PF-06882961 will be provided as tablets for oral administration.  Study  intervention 
(PF-06882961) must be administered BID within approximately  10minutes of com pletion of 
the morning and evening meals, approximately  10 hours apart.  Atorvastatin , midazolam or
the OC will be administered within approximately 10 minutes of completion of the morning 
meal.  PF-06882961 will be administered first and atorvastatin , midazolam or the OCwill be 
administered within 5 minutes of PF -06882961.
Part A – 64 days will be in- house as follows: Period 1 (SDatorvastatin): 4 day s;Period 2 
(SD midazola m):1day;Period 3 ( BID PF-06882961 titrated to 120 mg BID ): 31days ;
Period 4 (120 mg BID PF-06882961+ SD atorvastatin ): 3days;Period 5 (120 mg BID 
PF-06882961 + SD midazolam ): 1day;Period 6 (BID PF-06882961 titrated to 200 mg BID ): 
19days ; Period 7 (200 mg BID PF-06882961+ SD atorvastatin ): 3days;Period 8 (200 mg 
BID PF-06882961 + SD midazolam ): 2days.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 12Part B – 67 days will be in -house as follows: Period 1 (SD OC): 6 day s; Period 2 ( BID 
PF-06882961 titrated to 120 mg BID ): 31days;Period 3 (120 mg BI D PF-06882961 + SD 
OC) 5days;Period 4 (BID PF-06882961 titrated to 200 mg BID ) 19days;Period 5 (200 mg 
BID PF-06882961+ SD OC): 6days.
The FUvisit will occur 7-10 day s from the last dose of study  intervention and aFUcontact
will occur 28-35 days from thelast dose ofstudy  intervention .
Data Monitoring Committee or Other Independent Oversight Committee : 
This study  will not use a DMC .
Statistical Methods
The PK data for PF
-06882961, atorvastatin , midazolam , LE, and EEwill be anal yzed and 
reported separatel y.
Natural log e-transformed AUC inf(as data permit) of atorvastatin administered alone or 
co-administered with PF- 06882961 will be anal yzed using a mixed effect model with 
treatment as a fixed effect and participant as a random effect.  Estimates of the adjusted mean 
differences (Test -Reference) and corresponding 90% CIswill be obtained from the models.  
The adjusted mean differences and 90% CIsfor the differences will be exponentiated to 
provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIsfor 
the rati os.  The 2 test treatments will be ‘ atorvastatin and PF- 06882961 120 mg BID’ (Period 
4) and ‘ atorvastatin and PF -06882961 200 mg BID’ (Period 7), which will be reported 
separately  in comparison to the reference treatment of ‘ atorvastatin alone’ (Period 1).   The 
same anal ysis for natural log e-transformed C maxand AUC lastof atorvastatin will also be 
conducted.
Natural log e-transformed AUC inf(as data permit), C maxand AUC lastof midazolam 
administered alone or co -
administered with PF- 06882961 will be anal yzed and reported 
separately  using the same mixed effect model as described above for atorvastatin.  The 2 test 
treatments will be ‘midazolam and PF
-06882961 120 mg BID’ (Period 5) and ‘midazolam 
and PF- 06882961 200 mg BID’ (Period 8), which will be reported separately  in comparison 
to the reference treatment of ‘midazolam alone’ (Period 2).
Natural log e-transformed AUC inf(as data permit), C maxand AUC lastofLE and EE
administered alone or co -administered with PF- 06882961 will be anal yzed and reported 
separately  using the same mixed effect model as described above for atorvastatin.  For LE, 
the 2 test treatments will be ‘levonorgestrel and PF-06882961 120 mg BID’ (Peri od 3) and 
‘LE and PF-06882961 200 mg BID’ (Period 5), which will be reported separatel y in 
comparison to the reference treatment of ‘ LE alone’ (Period 1). Similarl y for EE, the 2 test 
treatments will be ‘ EEand PF -06882961 120 mg BID’ (Period 3) and ‘ EEand 
PF-06882961 200 mg BID’ (Period 5), which will be reported separatel y in comparison to 
the reference treatment of ‘ EEalone’ (Period 1).

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 131.2.Schema
PART A -Atorvastatin and Midazolam
PART B – O ral C ontraceptive
1.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures.  Refer to the 
STUDY ASSESSMENTS AND PROCEDURES section of the protocol for detailed 
information on each procedure and assessment required for compliance with the protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA 
table , in orde r to conduct evaluations or assessments required to protect the well -being of the 
participant.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 14The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA 
table , in order to conduct evaluations or assessments required to protect the well- being of the 
participant.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 15Part A : Schedule of Activities
Table 1. Part A -Overall Schedule of Activities Screening to Period 5
Visit Identifier
Abbreviations used in this table may 
be found in Appendix 9Screening Period 1
(Atorvastatin
only)Period 2
(Midazolam 
only)Period 3 
(PF-06882961 only)Period 4
(PF-06882961 + 
Atorvastatin )Period 5
(PF-06882961 + 
Midazolam)
Day in Study Perioda-28 to -2-1 12 3 1 12-7 8 9-14 15 16-22 23 24-3031 1 2 3 1
Days in Studyb-28 to -2-1 12 3 4 56-11 12 13-18 19 20-26 27 28-34 35 36 37 38 39
Informed consent & demography x
Outpatient visit (after ≥10-h fast) x
COVID -19 pre -screeningcx x
Temperature checkcx x                 
SARS -CoV -2 testingcx x xd
Inpatient stay at CRU x                
Eligibility Criteria x x
Medical history x
C-SSRS and PHQ -9 x x x x x x x
Review drug, alcohol/tobacco use x x
Review contraception use (WOCBP 
Only) (Section 5.3.4 )x x
Review prior or concomitant 
treatments x x                
AEmonitoring x x                
Standardized meals/snacksex               
Physical examf(height at Screen only) x
Body weight x
Table 2
Table 3x x x x
Table 4
Table 2
Table 3Supine 12 -lead ECG x x x x x
Single, supine vital signs assessmentgx x x x x
PF-06882961 administrationhx x x x x x x x x x
Atorvastatin administration
Midazolam administration
Blood Sampling for:i
-Chemistry x x x
-Hematology x x
-PT/INR/aPTT x x
-FSH,jHIV, HepBsAg, HCVAb, 
HCV RNA, C -peptidex
-HbA1c, TSH, lipids x x x

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 16Visit Identifier
Abbreviations used in this table may 
be found in Appendix 9Screening Period 1
(Atorvastatin
only)Period 2
(Midazolam 
only)Period 3 
(PF-06882961 only)Period 4
(PF-06882961 + 
Atorvastatin)Period 5
(PF-06882961 + 
Midazolam)
Day in Study Perioda-28 to -2 -1 12 3 1 12-7 8 9-14 15 16-22 23 24-30 31 1 2 3 1
Days in Studyb-28 to -2 -1 12 3 4 56-11 12 13-18 19 20-26 27 28-34 35 36 37 38 39
- Free T4, calcitonin, amylase, 
  lipase, total bile acidsxx x
- Serum pregnancy testjxx
- Atorvastatin & 
ortho-hydroxyatorvastatin PKxkxkxkxk
- Midazolam & 1-OH-midazolam PK xl
- PF-06882961 PK
-4 -β-hydroxycholesterol/cholesterol, 
EV
Urine Sampling for:
- Urine drug testnxx
- Urinalysis (and microscopy, as
appropriate)xx
a. Day relative to start of dosing Day 1 of that Period.
b. Day relative to first dose of investigational product (atorvastatin) on Day 1 of Period 1.
c. Participants will be tested for SARS-COVID-19 infection by PCR.  Test must be negative prior to admission (Period 1, Day 1). A  subsequent test will be 
done if they develop COVID-19 like symptoms.  Prior to SARS-CoV-2 test, temperature check and COVID-19 pre-screening (check expo sure to positive 
subject, residence or travel in area of high incidence and COVID-19 related signs and symptoms) will be done. See also Section 8.2.5 (COVID-19 Specific 
Assessments).
d. Participants will be tested for SARS-COVID-19 infection by PCR after 4 days; ie, completion of 4 x 24 hours in house, or if they d evelop COVID-19 like 
symptoms).  See also Section 8.2.5 (COVID-19 Specific Assessments).
e. Meals to be provided at approximately 0H, 4H, and 10H post AM dose; plus, snacks provided according to Section 5.3.1 .
f. Complete physical exam at Screening; otherwise, brief exam if findings during previous exam or new/open AEs, if appropriate, at investigator discretion.
g. Includes BP and PR predose.h. Dosing to occur BID with breakfast and dinner Section 5.3.1 .
i. Collection following fasting duration specified in Secti on 5.3.1 .
j. Testing in females only: Serum β-hCG for all WOCBP; FSH for ALL female participants to confirm PM status only.  Test result should confirm no 
pregnancy prior to dosing.CCI
PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 17k. Following atorvastatin dosing on Day 1 in both Periods 1 and 4, atorvastatin and ortho-hydroxyatorvastatin PK (same collection) should be obtained at 24H, 
36H, 48H and 72H post-dose.
l. Following midazolam dosing on Day 1 in both Periods 2 and 5, midazolam and 1-OH-midazolam PK should be obtained at approximat ely 24H post-dose 
(note - parent and metabolite require separate collections).
n. Participants may undergo random urine drug testing at the discretion of the investigator.CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 18Table 1.Part A -Overall Schedule of Activities Period 6 to ET
Visit Identifier
Abbreviations used in this table may be found in 
Appendix 9Period 6
(PF-06882961 only)Period 7
(PF-06882961 + 
Atorvastatin )Period 8
(PF-06882961 +
Midazolam)FU FU Contact 
TelephoneET
Day in Study Perioda1 2-8 9 10-18 19 1 2 3 1 2 - - -
Days in Studyb40 41-4748 49-57 58 59 60 61 62 63 69-72 90-97 -
Informed consent & demography
Outpatient visit (after ≥10-h fast) x
COVID -19 pre -screening
Temperature check          x x x
SARS -CoV -2testing x x
Inpatient stay at Clinical Research Unit          xc
Eligibility Criteria
Medical history 
C-SSRS and PHQ -9 x x x x x x
Review drug, alcohol/tobacco use x
Review contraception use (Section 5.3.4 ) x x x
Review prior or concomitant treatments    
Table 4
Table 2 
Table 3x x x x
AEmonitoring       x x x x
Standardized meals/snacksd     
Physical exam (height at Screen only) xexexe
Body weight x x x x x
Supine 12 -lead ECG x x x x x
Single, supine vital signs assessmentfx x x x x
PF-06882961 administrationgx x x x x x
Atorvastatin administration
Midazolam administration
Blood Sampling for :h
- Chemistry x x x x
-Hematology x x x
-PT/INR/aPTT x x x
-FSHi,HIV, HepBsAg, HCVAb, C-peptide
-HbA1c, TSH, lipids x x x
-Free T4, calcitonin, amylase, lipase, total bile acids x x x
-Serum pregnancy testix x x
-Atorvastatin & ortho-hydroxyatorvastatin PK xjxjx

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 19Table 1 . Part A - Overall Schedule of Activities Period 6 to ET
Visit Identifier
Abbreviations used in this table may be found in 
Appendix 9Period 6
(PF-06882961 only)Period 7
(PF-06882961 + 
Atorvastatin)Period 8
(PF-06882961 +
Midazolam)FU FU Contact 
TelephoneET
Day in Study Perioda1 2-8 9 10-18 19 1 2 3 1 2 - - -
Days in Studyb40 41-47 48 49-57 58 59 60 61 62 63 69-72 90-97 -
- Midazolam & 1-OH-midazolam PK x xkx
- PF-06882961 PK x
-4-β-hydroxycholesterol/cholesterol , EV
Urine Sampling for:
- Urine drug testl
- Urinalysis (and microscopy, as appropriate) x xx
a. Day relative to start of dosing Day 1 of that Period.
b. Day relative to first dose of investigational product (atorvastatin) on Day 1 of Period 1.c. Discharge from CRU. 
d. Meals to be provided at approximately 0H, 4H, and 10H post AM dose; Note that there is no PF-06882961 administration on Day 6 3. 
e. Complete physical exam at Period 8 Day 2,FU, and ET; otherwise, brief exam if findings during previous exam or new/open AEs, i f appropriate, at 
investigator discretion.
f. Includes BP and PR predose.g. Dosing to occur BID with breakfast and dinner.  Note that there is no PF-06882961 administration on Day 63. h. Collection following fasting duration specified in Secti on 5.3.1 .
i. Testing in females only: Serum β-hCG for all WOCBP; FSH for female participants to confirm PM status only.  
j. In Period 7, atorvastatin & ortho-hydroxyatorvastatin PK should be obtained at 24H, 36H, 48H, 72H post atorvastatin dose on D ay 1 of the same period. 
k. In Period 8, midazolam & 1-OH-midazolam PK should be obtained at approximately 24H post midazolam dose on Day 1 of the same per iod.
l. Participants may undergo random urine drug testing at the discretion of the investigator.CCI CCI
PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 20Table 2. Schedule of Activities – Day 1 of Period 1 (Atorvastatin ONLY), Period 4 (Atorvastatin + PF-06882961 
120 mg BID), and Period 7 (Atorvastatin + PF-06882961 200 mg BID)
Hours Relative to Dosing at 0H 0 0.5 1 1.5 2 4 6 9 10 12
Body Weight x
Supine 12-lead ECG x
Supine vital sign assessmentax
Atorvastatin administration x
PF-06882961 administration (Periods 4 and 7 only) xbxc
Blood sampling for:d
- Chemistr y(Periods 1 and 4 only) x
- Hematology (Periods 1 and 4 only) x
- Atorvastatin & ortho-hydroxyatorvastatin PK x x x x x x x x x
- PF-06882961 PK (Periods 4 and 7 only)fx
Urine sampling for:
- Urinalysis and microscopy, as appropriate ( Period 1 only )x
a. Includes BP and PR. 
b. Dosing expected to occur with breakfast.c. Dosing expected to occur with dinner.d. Collection following fasting duration according to dosing frequency as specified in Meals and Dietary Restrictions . 
f. For Periods 4 and 7 only, PF-06882961 PK sample to be drawn at 0H, approximately 24H after PF-06882961 morning dose on previo us day.CCI
CCI
CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 21Table 3. Schedule of Activities –Day 1 of Period 2 (Midazolam ONLY), Period 5 (Midazolam + PF -06882961
120mg BID) and Period 8 (Midazolam + PF-06882961 200 mg BID )
Hours Relative to Dosing at 0H 0 0.5 1 2 3 4 6 8 10 12 16
Supine 12 -lead ECG x
Supine vital sign assessmentax
Midazolam administration x
PF-06882961 administration (Periods 5 and 8 only) xbxc
Blood sampling for:d
-Atorvastatin & ortho-hydroxyatorvastatin PK x
-Midazolam & 1-OH-midazolam PK x x x x x x x x x x x
-PF-06882961 PK ( Periods 5 and 8 only) x
-4-β-hydroxycholesterol/cholesterol, EV x
a.Includes BP and PR . 
b.Dosing expected to occur w ith breakfast.
c.Dosing expected to occur w ith dinner.
d.Collection following fasting duration according to dosing frequency as specified in Meals and Dietary Restrictions .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 22Table 4. Schedule of Activities – Day 31 of Period 3 and Day 19 of Period 6 (PF- 06882961 only)
Hours Relative to Dosing at 0H 0 1 2 4 6 8 10 12 14
Supine 12 -lead ECG x
Supine vital sign assessmentax
PF-06882961 administration xbxc
Blood sampling for:d
-PF-06882961 PK x x x x x x x x x
Urine sampling for:
-Urinalysis and microscopy, as appropriate x
a.Includes BP and PR . 
b.Dosing expected to occur w ith breakfast.
c.Dosing expected to occur w ith dinner.
d.Collection following fasting duration according to dosing frequency as specified in Meals and Dietary Restrictions .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 23Part B: Schedule of Activities
Table 5. Part B -Overall Schedule of Activities through Period 5
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 9Screening Period 1
(OC only)Period 2
(PF-06882961 only)Period 3
(PF-06882961 
+ OC )Period 4
(PF-06882961 only)Period 5
(PF-06882961 + 
OC)
Day in Study Perioda-28 to -2-1 12-4 5 1 2-7 8 9-14 15 16-21 22 23-3031 12-4 5 1 2-8 910-
1819 1 2-5 6
Days in Studyb-28 to -2-1 12-4 5 6 7-12 13 14-19 20 21-26 27 28-35 36 37 38-
4041 4243-495051-
596061 62-
6566
Informed consen t & demography x
Outpatient visit (after ≥10-h fast) x
COVID -19 pre -screeningcx x
Temperature Checkcx x                       x
SARS -CoV -2 testingcx x xdx
Inpatient stay at CRU x                      x
Eligibility Criteria x x
Medical history x
C-SSRS and PHQ -9 x x x x x x x x x x x
Review drug, alcohol/tobacco use x x
Review prior or concomitant 
treatments x x                       x
AEmonitoring x x                       x
Standardized meals/snacksex                      x
Physical examf(height at Screen 
only)x x
Body weight x
Table 6x x x x
Table 7
Table 6x x
Table 7
Table 6x
Supine 12 -lead ECG x x x x x x x x
Single, supine vital signs 
assessmentgx x x x x x x x
PF-06882961 administrationhx x x x x x x x x x x x x x x
OCadministration

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 24Table 5. Part B - Overall Schedule of Activities through Period 5
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 9Screening Period 1
(OC only)Period 2
(PF-06882961 only)Period 3
(PF-06882961 
+ OC)Period 4
(PF-06882961 only)Period 5
(PF-06882961 + 
OC)
Day in Study Perioda-28 to -2 -1 12-4 5 1 2-7 8 9-14 15 16-21 22 23-30 31 12-4 5 1 2-8 910-
1819 1 2-5 6
Days in Studyb-28 to -2 -1 12-4 5 6 7-12 13 14-19 20 21-26 27 28-35 36 37 38-
4041 4243-49 5051-
596061 62-
6566
Blood Sampling for:i
-Chemistry x x x xx
- Hematology x x x
- PT/INR/aPTT x x x
- HIV, HepBsAg, HCVAb, HCV 
RNA, C- peptidex
- HbA1c, TSH, lipids x x x
- Free T4, calcitonin, amylase, 
lipase, total bile acidsxx x
- Serum FSHjx
- LE PK & 
EE PKxkxkxkxkxkxkxkxkxk
- PF-06882961 PK
Urine Sampling for:
-Urine drug testmxx
-Urinalysis (and microscopy, as 
appropriate)xx x
a. Day relative to start of dosing Day 1 of that Period.
b. Day relative to first dose of investigational product (OC) on Day 1 of Period 1.CCI
CCI
PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 25c. Participants will be tested for SARS-COVID-19 infection by PCR.  Test must be negative prior to admission (Period 1, Day 1). A  subsequent test will be 
done if they develop COVID-19 like symptoms.  Prior to SARS-CoV-2 test, temperature check and COVID-19 pre-screening (check expo sure to positive 
subject, residence or travel in area of high incidence and COVID-19 related signs and symptoms) will be done. See also Section 8.2.5 (COVID-19 Specific 
Assessments).
d. Participants will be tested for SARS-COVID-19 infection by PCR on Period 1, Day 4 (ie, completion of 4 days in house) and on Pe riod 5, Day 5 (ie, day 
prior to discharge), or if they develop COVID-19 like symptoms.  See also Section 8.2.5 (COVID-19 Specific Assessments).
e. Meals to be provided at approximately 0H, 4H, and 10H post AM dose.f. Complete physical exam at Screening, and Period 5 otherwise, brief exam if findings during previous exam or new/open AEs, if a ppropriate, at investigator 
discretion.
g. Includes BP and PR predose.
h. Dosing to occur BID with breakfast and dinner Section 5.3.1 . 
i. Collection following fasting duration specified in Secti on 5.3.1 .
j. FSH for female participants to PM status only.  k. Following OC dosing on Day 1 in Periods 1, 3 and 5, LE and EE PK should be obtained at approximately 24H, 48H, 72H, 96H and 1 20H post-dose.
m. Participants may undergo random urine drug testing at the discretion of the investigator.CCI
PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 26Table 5 .Cont. Part B - Overall Schedule of Activities FU to ET
Visit Identifier FU FU Contact Telephone ET
Day in Study Perioda- - -
Days in Studyb72-75 94-101 -
Informed consent & demography
Outpatient visit (after ≥10-h fast) x
COVID-19 pre-screening
Temperature check x
SARS-CoV-2 testing x
Inpatient stay at Clinical Research Unit
Eligibility Criteria
Medical history 
C-SSRS and PHQ-9 xx
Review drug, alcohol/tobacco use x
Review prior or concomitant treatments x x x
AE monitoring xx x
Standardized meals/snacksc
Physical exam (height at Screen only) xdxd
Body weight xx
Supine 12-lead ECG xx
Single, supine vital signs assessmentexx
PF-06882961 administration
OC administration
Blood Sampling for:f
- Chemistry xx
- Hematology xx
- PT/INR/aPTT xx
- FSH ,HIV, HepBsAg, HCVAb, C-peptide
- HbA1c, TSH, lipids xx
- Free T4, calcitonin, amylase, lipase, total bile acids x x
-LE PK and EE PK x
-PF-06882961 PK x
Urine Sampling for:
- Urine drug testg
- Urinalysis (and microscopy, as appropriate) x xCCI
CCI CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 27Table 5.Cont. Part B -Overall Schedule of Activities FU to ET
Visit Identifier FU FU Contact Telephone ET
Day in Study Perioda- - -
Days in Studyb72-75 94-101 -
a.Day relative to start of dosing Day 1 of that Period.
b.Day relative to first dose of investigational product ( OC) on Day 1 of Period 1 .
c.Meals to be provided at approximately 0H, 4H, and 10H post AM dose; Note that there is no PF -06882961 administration on Day 62. 
d.Brief exam if findings during previous exam or new/open AEs, if appropriate, at investigator discretion.
e.Includes BP and PR predose.
f.Collection following fasting duration specified i n Section 5.3.1 .
g.Participants may undergo random urine drug testing at the d iscretion of the investigator.

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 28Table 6. Schedule of Activities – Day 1 of Period 1 (OC ONLY), Period 3 (OC + PF-06882961 120 mg BID) and 
Period 5 (OC + PF 06882961 200 mg BID)
Hours Relative to Dosing at 0H 0 0.5 1 1.5 2 4 8 10 12
Body weight x
Supine 12-lead ECG x
Supine vital sign assessmentax
OC administration x
PF-06882961 administration (Periods 3 and 5 only) xbxc
Blood sampling for:d
- Chemistr y(Period 1 only) x
- LE PK and EE PK x x x x x x x x
-PF-06882961 PK (Periods 3 and 5 only) x
a. Includes BP and PR. 
b. Dosing expected to occur with breakfast.c. Dosing expected to occur with dinner.d. Collection following fasting duration according to dosing frequency as specified in Meals and Dietary Restrictions .
e. If not collected on the designated collection day, collect at the next available time point when biospecimens are being colle cted in conjunction with a 
participant visit.CCICCI
CCI CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 29Table 7. Schedule of Activities –Day 31 of Period 2 and Day 19 of Period 4 (PF- 06882961 only)
Hours Relative to Dosing at 0H 0 1 2 4 6 8 10 12 14
Supine 12 -lead ECG x
Supine vital sign assessmentax
PF-06882961 administration xbxc
Blood sampling for:d
-Chemistry (Period 2 only) x
-Hematology (Period 2 only) x
-PT/INR/aPTT (Period 2 only) x
-HbA1c, TSH, lipids (Period 2 only) x
-Free T4 , calcitonin, amylase, 
  lipase, total bile acids (Period 2 only)x
-PF-06882961 PK x x x x x x x x x
Urine sampling for:
-Urinalysis and microscopy, as 
appropriate x
a.Includes BP and PR . 
b.Dosing expected to occur w ith breakfast.
c.Dosing expected to occur w ith dinner.
d.Collection following fasting duration according to dosing frequency as specified in Meals and Dietary Restrictions .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 302.INTRODUCTION
PF-06882961 is an oral GL P-1R agonist that is currentl y being developed for the treatment of
type 2 diabetes mellitus (T2DM) and obesit y. 
GLP-1is a neuroendocrine hormone that is predominantly  released from the small intestine 
in response to food intake.1  GLP - 1 activation of the GL P-1R stim ulates insulin release, 
inhibits glucagon secretion in a glucose- dependent manner, and delay s gastric empty ing.2,3  
In addition, GL P-1 has been shown to increase satiety  and suppress food intake.4
PF-06882961 has been demonstrated, in nonclinical models, to stimulate glucose -dependent 
insulin release and suppress food intake with equivalent efficacy  to an injectable peptide 
GLP-1R agonist.  
2.1.Study Rationale
The purpose of this Phase 1, open- label, fixed -sequence stud y is to evaluate the effect of 
2dose levels of PF -06882961 administered to steady  state on the SD pharmacokinetics of 
1)atorvastatin and midazolam in healthy  adult male and female participants (Part A), and 
2)an OC in health y PM female participants (Part B). The intent of this study  isto generate 
safet y, tolerabilit y, and pharmacokinetic data for further clinical development .
2.2.Background 
T2DM is estimated to affect more than 424 million people worldwide ,5and the prevalence of 
T2DM within the USis estimated to range from 12 to 14% .6  Patients with poorly  controlled 
T2DM have an increased risk of developing complications associated with both 
microvascular and macrovascular disease, including nephropathy , neuropathy , retino
pathy, 
cardiovascular disease and stroke; and are at 2 to 4 times increased risk of mortality  than 
adults who do not have diabetes.7  While existing pharmacological options for the treatment 
of diabetes may  provide satisfactory  glycemic control for some patients, there remains a large 
number of patients who do not achieve target gl ycated HbA1c levels, suggesting a need for 
additional therapeutic option s.
Obesity  is a chronic disease that is associated with serious co- morbidities, including T2DM, 
dyslipidemia, hy pertension, atherosclerosis, obstructive sleep apnea and certain cancers,8and 
is also associated with increased all cause mortality.9  The global burden of obesity  is high 
with more than 600 million adults estimated to have obesity  worldwide.  In addition, the 
prevalence of obesity  has doubled in more than 70 countries since 1980 and poses a major 
public health challenge.10First line treatment for obesity  is lifest yle intervention including 
diet, exercise and behavioral therap
y.  While effective in many patients, lifestyle intervention 
is often not sustainable, and many patients regain weight after initial weight loss.11
Pharmacotherap y has been approved for the long term treatment of obesity and can be a 
useful adjunct to lifest yle intervention to augment and maintain weight loss.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 31Marketed injectable GLP -1R agonists have demonstrated robust gly cemic efficacy , weight 
loss, and cardiovascular safet y, with more than one marketed agent demonstrating 
cardiovascular benefit.12  Based on the clinical history  of injectable GLP -1R agonists, an 
oral, small molecule GLP- 1R agonist is expected to improve glucose control and reduce 
HbA1c levels in patients with T2DM, while decreasing appetite a nd body  weight , resulting in 
weight loss in patients with 
T2DM and obesity , while avoiding the subcutaneous injection 
required b y currently  available peptidic GL P-1R agonists.
2.2.1. Nonclinical Pharmacology
In vitro primary  PDstudies demonstrated that, in cells expressing recombinant human and 
cynomolgus monkey  GLP -1R, PF -06882961 dose dependentl y promotes cAMP production.  
In vivo, PF -06882961 potentiated glucose stimulated insulin secretion during an IVGTT in 
cynomolgus monk eys in a dose -and concentration -dependent manner.  PF -06882961 was 
also shown to reduce food intake in cy nomolgus monkey s.  In all in vivo studies, efficacious 
plasma levels of PF -06882961 were consistent with the in vitro potency .  
Refer to the IB for m ore details on the nonclinical pharmacology  of PF -06882961 .
2.2.2. Nonclinical Pharmacokinetics and Metabolism
The oral PK of PF -06882961 in rats and monkey s indicated rapid absorption with 
bioavailability  ranging from 5% to 12%.  In repeat oral dose toxicity  studies in rats and 
monkey s, systemic exposure of PF- 06882961 increased with increasing dose, with no 
accumulation. 
Metabolism studies demonstrat ed low turnover of PF -06882961 with some oxidative and 
glucuronide metabolites.  All metabolites detected in huma n hepatocy tes were also observed 
in hepatocy tes from nonclinical species.  PF -06882961 is expected to be cleared via hepatic 
uptake b y OATP, followed by metabolic clearance principall y mediated b y CYP (3A4/5, 
followed b y CYP2C8, and CYP2C19).  Non CYP enzy mes also contributed to the 
metabolism of PF -06882961.
Based on in vitro data, PF -06882961 has the potential to inhibit intestinal BCRP with an
IC50= 0.8 µ M.  
Based on in vitro data, PF -06882961 did demonstrate time -dependent inhibitory  activity  of 
CYP3A 4/5-mediated midazolam 1’ -hydroxy lase and testosterone 6 -hydroxy lase activities. 
The rate of inactivation was not saturated within the concentration ranges tested (5 to 
150 µ M), and therefore, the K Iand k inactcould not be calculated.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 32In vitro data also suggest a risk of PF -06882961 interaction with drugs for which CYP2C8 
and UGT1A1 mediated metabolism constitutes the primary  mechanism of clearance.  At the 
dose of 200 mg BID, there is also a possibility  of weak inhibition of hepatic OATP1B3, 
OATP2B1, OC T1 and uptake transporter MDR1.  Static modeling of in vitro data also 
indicate that PF- 06882961 has a low potential to cause DDIs as a result of induction of 
CYP3A4, or inhibition of other CYP enzy mes (1A2, 2B6, 2C9, 2C19 or 2D6), other UGT 
enzy mes (1A4, 1A6, 1A9, 2B7, 2B15), and uptake transporters OATP1B1, OCT2, MATE1, 
MATE 2K, OAT1 and OAT3.  See Section 6.8 foruse of permitted and prohibited
medications.  
Refer to 
the IB for more details on the nonclinical PK and metabolism of PF -06882961.
2.2.3. Nonclinical Safety
General toxicology  studies have been completed in cy nomolgus monkey s up to 6 months in 
duration (with a 3- week lead -inand 1 -month recovery ) and in rats up to 6 months in duration 
with a 1- month recovery .  The exposure limits for plasma concentrations of PF -06882961 for 
clinical studies are based on the exposure at the NOAEL dose of 250 mg/kg/day  in the 
6-month with 1 -month rec overy  toxicology  study  in rats, due to the fact that findings in 
monkey s such as decreased food intake and body  weight loss are reversible and monitorable 
in a clinical setting. In the 6- month toxicity  study  in rats with 1- month recovery  the NOAEL 
was 250 mg/kg/day  based on species specific toxicity  at a higher dose.  The exposure
margins at 250 mg/kg/day  were 41-fold (C max, free) and 23- fold (AUC 24,free), to the 
predicted human exposures at the highest planned dose of PF -
06882961 in this study , which 
is 200 mg BID.
A NOAEL was not established in the cy nomolgus monkey  6month toxicity  study  with 
3-week lead -in and 1 -month recovery , due to early  euthanasia of 3 animals administered 
≥50mg/kg/day  who had clinical signs associated with adverse microscopic fin dings in the 
kidney  and heart ,which were unique to this study and had not been observed in animals 
exposed for longer duration in previous studies with similar doses.  Based on the available 
data, none of the microscopic findings observed in these moribun d animals appear to be 
consistent with primary  toxicological effects.  Rather, they  are more consistent with 
secondary  events related to prolonged inanition and the resulting negative energy  state.  
Exposure margins at 50 mg/kg/day  were 0.71- and 5.1-fold for Cmax(free) in males and 
females, respectivel y, and were 0.41- and 2.2 -fold for AUC 24(free) in males and females, 
respectivel y, to the predicted human exposures at the highest planned dose of PF - 06882961 
in this study  (200 mg BID) .
Other toxicology  studies completed in cy nomolgus monkey s include a 14-w eekstudy  with a 
4-week lead -in (18 weeks total exposure ) and a 13-week investigative toxicology  stud y with 
3-week lead- in(16weeks total exposure ), in which the NOAELs were 100 mg/kg/ day and 
150mg/kg/day  (highest dose administered), respectively .  At the NOAEL dose of 
100mg/kg/day  in the 14- week stud y with 4 -week lead -in, exposure margins were 1.6-fold 
and 1.2-fold for C max(free) and AUC 24(free) , respectivel y, based on the lack of adverse 
findings in animals that survived to the scheduled necrops
y.  At the NOAEL dose of 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 33150mg/kg/day  in the 13- week stud y with 3 -week lead -in, exposure margins were 9.5-and 
6.9-fold for Cmax(free) in males and females, respectivel y, and were 8.8 -and 7.9-fold for 
AUC 24(free) in males and females, respectivel y
, based on the absence of adverse effects in 
the study .  These exposure margins are versus the predicted human exposures at the highest 
planned dose of PF -06882961 in this study  (200 mgBID).
Embry o fetal developmental studies were completed in rats and rabbits.  Based on the lack of 
maternal toxicity  or adverse effects on embry o-fetal development, the NOAEL  for maternal 
and developmental toxicity  in rats was 500 mg/kg/day  (highest dose evalu ated).  The 
exposures at 500 mg/kg/day  provide margins of approximately  81
-fold (C max, free) and 
105-fold (AUC 24, free), to the predicted human exposures at the highest dose of 
PF-06882961 in this study  (200 mg BID).
In embry o fetal studies conducted in ra
bbits, the NOAEL for maternal and developmental 
toxicity  was 250 mg/kg/day , with margins of approximately  18-fold (C max, free) and 5.5 -fold 
(AUC 24, free), to the predicted human exposures at the highest dose of PF -06882961 in this 
study  (200 mg BID).
PF-06882961 was negative in genetic toxicity  testing and photosafet y endpoints.  A risk 
assessment of the target organ toxicities noted in the repeat dose toxicity  studies is provided 
in the IB.  
Refer to 
the IB for more details on the nonclinical safet y of PF -06882961.
2.2.4. Clinical Overview and Safety
Three clinical studies have been completed with PF -06882961 in which 135 participants 
were dosed, and 110 participants were exposed to single or multiple doses of PF -06882961 
(Table 6 -1 in the PF -06882961 IB). In addition, ongoing studies include a 16 -week ,Phase 2 
dose-ranging study  in T2DM (C3421005), a MD PK/PD study  in Japanese participants with 
T2DM (C3421015), a SD ADME and oral bioavailability  study  (C3421009), and a SD
formulation comparison study  in health y participants (C3421010). 
Two studies, C3421001 andC3421003, were completed in health y participants (total of 
37healthy participants randomized .  One study , C3421002, was completed in participants 
with T2DM (total of 98 T2DM participants randomiz ed).Inthese studies, PF -06882961 was 
found to be generall y safe and well tolerated. In C3421001, 25 healthy  participants were 
randomized to single ,ascending ,oral doses of PF -06882961 or placebo.   In C3421003, 
12healthy  participants were randomized to receive single doses of different oral formulations 
of PF -06882961.  In C3421002, 98 participants with T2DM were randomized to multiple ,
ascending ,oral doses of PF -06882961 or placebo for 28 day s. In this study PF-
06882961 
doses ranging from 10  mg BID to 120 mg BID were studied.   A total of 98 participants with 
T2DM on a background anti-diabetic regimen of metformin were randomized to receive 
PF-06882961 or matching placebo in a 3:1 randomization ratio, and 92 participants 
completed the study .  Six partic ipants discontinued from the study , of which 
2discontinuations were due to treatment -related TEAEs ,and 4 withdrew during the 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 34treatment or follow -up period for non- treatment related reasons. A total of 319 TEAEs were 
reported, of which themajority  of the AEs [294 (92%)] were mild in severity , 23 (7%) were 
moderate, and 2 (1%) were severe in intensity .  The most frequentl y reported TEAEs were
nausea (49.0%), d yspepsia (32.7%), vomiting (26.5%), diarrhea (24.5%), headache (23.5%),
andconstipation (20.4% ).One participant experienced a mild TEAE of h ypogl ycemia.
  This 
AE was non -fasting, mild in severity  and of limited duration.  There were no deaths and no 
treatment -related SAEs with repeat dosing of PF -06882961 in patients with T2DM. Overall, 
the dose s of PF -06882961 studied in C3421002 were safe and well -tolerated.
Preliminary  clinical and safet y data are available from the C3421007 Phase 1 study, which 
assessed the effect of PF -06882961 on the PKof rosuvastatin and midazolam.  I n this study , 
PF-
06882961 doses up to 200 mg BID were administered with 4 -day titration steps in 
16otherwise healthy , adult participants with obesity .  Of these participants, 14 completed the 
17-week stud y duration, and 2 participants discontinued for reasons not related to A Es.  A 
total of 129 TEAEs have been reported to date, of which the majority  of the AEs (127/129) 
were mild in severit y and 2 were moderate.  There was 1 mild TEAE of increased 
trans aminitis (also reported as an SAE), which occurred at the end of the dosing duration, 
after co
-administration of PF -06882961 200 mg BID with single doses of rosuvastatin 10 mg 
and midazolam 2 mg, administered separatel y in successive periods.  The transaminase levels 
returned to baseline levels in the FU period.  No significant e levations were noted in total 
bilirubin, alkaline phosphatase or GGT.  The most frequentl y reported all causality TEAEs in 
the study  participants have been nausea (26), constipation (12), decreased GFR (12), 
headache (10), and vomiting
(9).  While there we re isolated values for laboratory  tests, vital 
signs and ECG intervals outside of the reference ranges, no clear adverse trends were 
apparent in these parameters.  In this study , body  weight loss was noted with a mean percent 
change from baseline of 10.1% by the end of the dosing period.  Mild declines from baseline 
were noted in GFR, with most values remaining above 70 mL /min.  These declines in GFR
occurred in the setting of weight loss, which was expected based on the mechanism of action
of PF -06882961.  Most GFR levels returned to pre -dose levels by  the follow - up visit.  
2.2.4.1. Clinical Pharmacokinetics
The clinical PK of PF -06882961 in adult participants has been evaluated in 3 completed 
studies: C3421001, C3421002 and C3421003.  The results of these comple ted studies are 
summarized in the PF -06882961 IB.  
In Study C3421001, PF -06882961 appeared to demonstrate linear PK in healthy  participants
following single, oral doses ranging from 3 mg to 300 mg under fasted conditions .  Median 
Tmaxranged from 2.0 to 6 .0hours post dose , while m ean t ½values ranged from 4.3 to 
6.1hours. 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 35In Study C3421002, following 28 day s of dosing to participants with T2DM, accumulation 
was modest for the BID IR formulation treatments, with mean ratios based on dose 
normalized AUC 24(Rac) values ranging from 1.203 -2.009.  Day 28 plasma exposure as 
measured b y geometric mean AUC 24values appeared to increase in an approximate dose 
proportional manner across all I R treatments.  Mean t ½values on Day 28 across all 
treatments ranged from 4.681 to 8.090 hours, and no apparent trends were observed across 
various treatments, regimens, or doses administered.  I nter-participant variability  for 
PF-06882961 exposure based on geometric mean values w as 31%- 87% for AUC 24and 
32%- 94% for C maxon Day 28 across all treatments and cohorts.  A population PK model 
based on data from C3421001 and C3421002 indicated that the exposure in T2DM 
participants (C3421002) was approximately  1.7-fold higher than that observed in healthy  
participants (C3421001) after accounting for differences in bod y weight between the 
participants in each study.
Preliminary  PK data from study  C3421007 suggest induction of CYP3A based on 
observations of decreases in midazolam AUC lastand C maxof 49% and 37%, respectivel y, 
during co -
administration with PF-06882961 120 mg BID, and decreases in midazolam 
AUC lastand C max of 49% and 29%, respectivel y, during co -administration with PF- 06882962 
200mgBID.  Midazolam median Tmaxoccurred 0.5 hours earlier during PF -06882961 
co-administration at both the 120 mg BID and 200 mg BID dosing regimens.  Additionally , 
mean t1/2wereshorter for both the 120 mg BID and 200 mgBID PF-06882961 dose groups
at 6.6 hr (23% CV) and 6.9 hr (26% CV), respectively , vs 8.1 hr (25% CV) during 
administration of midazolam alone . Finall y,the 1- hydroxy-midazolam/midazolam 
(metabolite/parent) ratios increased during co -administration with PF -06882961, providing 
further support for CYP3A induction.  To further investigate the mechanism of this 
interaction, plasma 4- -hydroxycholesterol/cholesterol and EV samples, used as endogenous 
probes for CYP3A induction, will be collected and anal yzed in this study .
Based on preliminary  PK data from S tudy C3421007 , increases in rosuvastatin AUC lastand 
Cmaxof 2.0-fold and 2. 6-fold, respectively, were observed during co -administration with 
PF-06882961 120 mgBID, while increases for AUC lastand C maxof 2.8-fold and 4.4-fold,
respectivel y,were observed during co- administration with PF-06882962 200 mg BID.  
Systemic exposures of PF -06882961 (both AUC lastand C max) increased in a greater than 
dose-proportional manner from the 120 mg BID to the 200 mg BID dose in Study  C3421007.  
Dose -normalized AUC lastand C maxwere 18.4 ng*hr/mL  and 1.3 ng/mL, respectivel y, 
following 120 mg BID administration, and 29.8 ng*hr/mL and 2.8 ng/mL, respectivel y, 
following 200 mg BID administration.
2.3.Benefit/Risk Assessment
PF-06882961 is not expected to provide an y clinical benefit to the healthy  adult male and 
female participants or healthy  PM female participants in this study .  This study  is designed 
primarily  to generate safety , tolerability , and 
PK data for further clinical development.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 36More detailed information about the known and expected benefits and risks and reasonabl y 
expect ed AEs of PF -06882961 may  be found in the IB, which is the SRSD for this study .  
The SRSD for the site sourced atorvastatin (eg, Lipitor ) product is the USPI.13The SRSD for 
the site sourced midazolam ( midazolam hy drochloride sy rup) product is the USPI .13The 
SRSD for the site sourced OC (0.15 mg LE/0.03 mg EE
)product is the USPI .14
2.3.1. Risk Assessme nt
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention PF-06882961
Thyroid C -cell tumors The potential risks are based on product 
labeling for injectable GLP -1R agonists 
(ie, liraglutide, dulaglutide, and 
exenatide) due to dose- dependent and 
treatment duration -dependent thyroid 
C-cell tumors in nonclinical studies in 
rats and mice at clinicall y relevant 
exposures. 
Thyroid C -cell tumors have not been 
observed with PF -06882961 in clinical 
or nonclinical studies.Potential participants with a 
personal or family history of 
medullary thyroid carcinoma or 
MEN2 are excluded from the 
clinical development program.  
Thyroid function tests are included 
in the clinical trial protocols to 
monitor participants’ thyroid 
function.  
Pancreatitis The potential risks are based on product 
labeling for injectable GLP -1R ago nists 
(ie, liraglutide, exenatide and 
dulaglutide). 
Pancreatitis has not been observed in the 
PF-06882961 clinical trial program.Per exclusion criteria, potential 
participants with acute pancreatitis 
or a history of chronic pancreatitis 
are not eligible for study entry.  
Serum amylase and lipase are 
monitored during the clinical 
studies.  
Hypoglycemia Clinical trials with injectable GLP -1R
agonists have not demonstrated an 
increased risk for hypoglycemia.  
How ever, when administered in 
combination with anti -diabetic agents 
that are known to have an increased risk 
of hypoglycemia (such as insulin or 
sulfonylureas), an increased risk for 
hypo glycemia was observed.  
Participants with obesity who do not 
have co -existing T2DM would not be 
taking anti -diabetic agents and therefore 
would not be expected to have an 
increased risk for hypoglycemia.  
Only one AEof mild hypoglycemia has 
been reported in the clinical development 
program to date.Anti-diabetic medications are 
prohibited in this study, and blood 
glucose is monitored as a part of the 
lab assessments at every clinical 
visit in this study.  Participants are 
informed about the signs and 
symp toms of hypoglycemia, and 
are monitored for these symptoms 
during the study.
Impairm ent in renal 
functionIn rats, minimal renal tubular 
vacuolation was observed, but this 
finding was considered to be 
non-adverse.Per exclusion criteria, potential 
participants with significant renal 
impairm ent are not eligible for 
study entry.  Renal function is 
monitored at frequent intervals by 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 37In the clinical trial program only one 
mild adverse event (Preferred Term 
Blood creatinine increased) has been 
observed in the clinical trial program.lab assessments of serum BUN , 
creatinine and eGFR.
Gastrointestinal adverse 
reactionsThe potential risks are based on product 
labeling for injectable GLP -1R agonists 
(ie, liraglutide, exenatide and 
dulaglutide).
In addition, gast rointestinal AEs, the 
majority of which were mild in severity, 
have been observed in the clinical 
program with PF -06882961.  In 
nonclinical studies with PF -06882961, 
gastrointestinal adverse effects have 
been seen in rats and monkeys.Participants are monitored during 
the clinical studies to prevent 
potential sequelae of any severe 
gastrointestinal reactions, 
eg,dehydration.  Concomitant 
medication for nausea is permitted 
in the study.  Additionally, 
PF-06882961 w ill be titrated from 
10 mg BID dose to 120 mg BID 
over 28 days and from 120 mg BID 
to 200 mg BID over 16 days in the 
study. 
Diabetic retinopathy 
complicationsThe potential risk is based on the product 
labeling for the injectable GLP -1R 
agonist semaglutide for T2DM .  This 
risk has not been listed in the prescribing 
information for other marketed GLP -1R 
agonists.
There are no nonclinical or clinical data 
involving PF -06882961 to suggest an 
increased risk of diabetic retinopathy 
complications.Potential participants with diabetes 
mellitus are exclud ed from this 
clinical study.
Suicidal ideation and 
behaviorThe potential risk is based on the product 
labeling for the injectable GLP -1R 
agonist liraglutide for obesity.  This risk 
has not been listed in the prescribing 
information for other marketed GLP -1R 
agonists for T2DM .
There are no nonclinical or clinical data 
involving PF -06882961 to suggest an 
increased risk of suicidal ideation and 
behavior.Suicidal ideation and behavior, 
along with symptoms of depression, 
will be monitored at frequent 
interval s during the study using the 
C-SSRS and PHQ -9 questionnaires, 
with referral to a MHP for further 
evaluation if needed.
Changes in heart rate and 
blood pressureIncreases in HRhave been reported for 
marketed GLP -1R agonists, and 
increases in HRhave been observed w ith 
PF-06882961 administration, with most 
HR values within the normal range.  In 
addition, declines in systolic blood 
pressure have been noted at higher doses 
of PF -06882961.HR and BP are monitored at 
frequent intervals during the 
clinical study.
Declines in body weight Decreased appetite and body weight loss 
have been reported for marketed 
GLP -1R agonists, and declines in body 
weight have been noted at higher doses 
of PF -06882961.Weight is collected at multiple 
timepoints and will be monitored 
throughout the trial.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 38Acute gallbladder disease The potential risk is based on the product 
labeling for the injectable GLP -1R 
agonist liraglutide for obesity and also 
exenatide.  
Acute gallbladder disease has not been 
observed in the PF -06882961 clinical 
trial program to date.Participants with symptomatic 
gallbladder disease are excluded 
from this clinical study. 
Participants are monitored for AEs
and laboratory tests that may 
suggest development of acute 
gallbladder disease.
Study Intervention : Atorvastatin
Skeletal muscle effects: 
These risks can occur at 
any dose level, but are 
increased at the highest 
dose ( 80 mg).  Concurrent 
administration of some 
lipid-lowering therapies 
(fibrates or niacin) 
increases the risk of 
adverse skeletal muscle 
effects.Risk based on product labeling. Single dose of 20 mg is 
administered in th isstudy and poses 
minimal risk.  Other lipid -lowering 
therapies will not be administered 
as concomitant m edications in this 
study.
Liver enzyme 
abnormalities.Risk based on product labeling. Single dose of 20 mg is 
administered in th isstudy and poses 
minimal risk.  Liver enzymes will 
be monitored throughout the study 
as part of the safety labs.
Study Inter vention: Midazolam
Respiratory depression Risk based on product labeling. A single dose of 5mg is 
administered in the study and poses 
minimal risk.  Participants will be 
monitored in an inpatient clinical 
research unit.
Study Intervention : LE/EE
Increased BP. Risk based on product labeling. A single dose of 0.15 mg LE/0.03 
mg EEisadministered in th isstudy 
and poses minimal risk.  
Participants will be monitored in an 
inpatient clinical research unit.
Other
Risk of COVID -19 
exposure during studyDuring the pandemic, study participants 
could be infected with the SARS -CoV -2 
virus during study participation. This 
could lead to increased health risk for 
this participant and others in the study.Participants undergo COVID -19 
specific assessments prior to 
admission to study site and 
according to SOA .
2.3.2. Benefit Assessment
While PF -06882961 is not expected to provide any  clinical benefit to the healthy  participants
in this short -term study , potential benefits may  include receiving medical evaluations/
assessments associated with clinical study  visits (eg ,physical examinations, ECGs, l abs), and 
contributing to the process of developing a potential new therap y for T2DM and obesity .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 39More detailed informa tion about the known and expected benefits and risks and reasonabl y 
expected AEs of PF-06882961 may  be found in the IB, which is SRSD for this study .
2.3.3. Overall Benefit /Risk Conclusion
Considering all available clinical and nonclinical data, the benefit -risk profile of 
PF-06882961 supports clinical development in participants with T2DM and obesity .
Taking into account the measures to minimize risk to study participants
, the potential risks 
identified in association with PF-06882961 are justified by  the anticipated benefits that may  
be afforded to participants with PF-06882961.
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Part A
Prim ary: Prim ary: 
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of atorvastatin in healthy 
male and female adult participants. 
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of midazolam in healthy 
male and female adult participants. Atorvastatin plasma pharmacokinetic param eters: 
AUC inf(if data permit *otherwise AUC last) in 
Periods 1, 4 and 7.
Midazolam plasma pharmacokinetic parameters: 
AUC inf(if data permit *otherwise AUC last) in 
Periods 2, 5 and 8.
Secondary: Secondary: 
To evaluate the safety and tolerability of 
PF-06882961 administered separately and in 
combination with atorvastatin or midazolam in 
healthy male and female adult participants.Assessment of TEAEs , clinical laboratory 
abnormal ities, vital signs, body weight, and ECG 
parameters during Part A of the study.
Assessment of mental health as determined by 
C-SSRS and PHQ -9during Part A of the study.
Tertiary/Exploratory: Tertiary/Exploratory: 
To evaluate the effects of PF -06882961 on 
additional pharmacokinetic parameters of 
atorvastatin and midazolam in healthy male 
and female adult participants.
To evaluate the MDpharmacokinetics of PF -
06882961 in healthy male and female adult 
participants.
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of 
ortho -hydroxyatorvastatin in healthy male and 
female adult participants.
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of 1 -OH-midazolam in 
healthy male and female adult participants.Additional plasm apharm acokinetic parameters for 
atorvastatin (Periods 1, 4 and 7) and midazolam 
(Periods 2, 5 and 8): C max, Tmax, CL/F, Vz/F, t ½, as 
data permit.
PF-06882961 plasma pharmacokinetic parameters 
at Days 35 and 5 8: AUC 24, Cmax, Tmax.
Ortho -hydroxyatorvastatin plasma 
pharmacokinetic parameters: AUC last, Cmax, Tmax; 
and AUC infand t ½as data permit in Periods 1, 
4and 7.  Metabolite/parent 
(ortho -hydroxyatorvastatin/ atorvastatin) ratios 
will also be calculated.
1
-OH-midazolam plasma pharmacokinetic 
parameters: AUC last, Cmax, Tmax; and AUC infand t ½
as data permit in Periods 2, 5 and 8.  

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 40To evaluate the effects of PF -06882961 on 
biomarkers of CYP3A induction. [Optional] .Metabolite/parent (1 -OH-midazolam/midazolam) 
ratios w ill also be calculated.
Morning predose 
4--hydroxycholesterol/cholesterol plasma ratio 
on Day 1 in Periods 2, 5, and 8.  Morning predose 
plasma -derived EV on Day 1 in Periods 2, 5, and 
8.
Part B
Prim ary: Prim ary: 
To evaluate the effects of PF -06882961 on the 
pharmacokinetics of an OC(LE/EE) in 
healthy PMfemale participants.LEplasma pharmacokinetic parameters: AUC inf(if 
data permit *otherwise AUC last) in Periods 1, 
3and 5.
EEplasma pharmacokinetic par ameters: AUC inf(if 
data permit *otherwise AUC last) in Periods 1, 
3and 5.
Secondary: Secondary: 
To evaluate the safety and tolerability of 
PF-06882961 administered separately and in 
combination with an OC(LE/EE) in healthy 
PMfemale participants.Assessment of TEAEs , clinical laboratory 
abnormalities, vital signs, body weight, and ECG 
parameters during Part B of the study.
Assessment of mental health as determined by 
C-SSRS and PHQ -9 in Part B of this study.
Tertiary/Exploratory: Tertiary/Exploratory: 
To evaluate the effects of PF -06882961 on 
additional pharmacokinetic parameters of an 
OC(LE/EE ), adm inistered separately, in 
healthy PMfemale participants.
To evaluate the MDpharmacokinetics of 
PF-06882961 in healthy PMfemale 
participants.Additional plasm apharm acokinetic parameters for 
LE and EE (both in Periods 1, 3 and 5): C max, Tmax, 
CL/F, Vz/F, t ½, as data permit.
PF-06882961 plasma pharmacokinetic parameters 
at Days 36 and 6 0: AUC 24, Cmax, Tmax.
* Should it be deemed that too few AUC infestimates (eg, less than 12 for a single treatment) are obtained 
from the evaluable participants, AUC lastmay be selected as the primary endpoint for CSR reporting.  This 
will be considered for the atorvastatin , mida zolam ,LE and EE objectives separately.
4.STUDY DESIGN
4.1.Overall Design
This study will be conducted in 2 parts.  Part A will evaluate the effect of 2 steady -state dose 
levels of PF -06882961 on the SD pharmacokinetics of atorvastatin and midazolam .  Part B 
will evaluate the effect of 2steady -state dose levels of PF-06882961 on the SD
pharmacokinetics of an OC.  Participants will participate in either Part A or Part B (not both), 
and Parts A and B expected to be conducted in parallel, if possible.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 41All participants will provide informed consent and undergo Screening evaluations to 
determine their eligibility.  Screening will occur within 28 day s of the first dose of study  
intervention on Day  1of Period 1 for both Parts A and B .  Participants who dis continue from 
the study  before completing all assessments may  be replaced at the discretion of the 
investigator and Sponsor.
PF-06882961 will be provided as tablets for oral administration.  Study  intervention 
(PF-06882961) must be administered BID within approximately  10minutes of completion of 
the morning and evening meals, approximately  10 hours apart.  Atorvastatin, midazolam and 
the OC will be administered within approximately 10 minutes of completion of the morning 
meal.  PF-06882961 will be administered first and atorvastatin, midazolam or OC will be 
administered within 5 minutes of PF -06882961.
4.1.1. Part A
Part A of this study is anopen -label, 8 -period, fixed -sequence stud y to evaluate the effect of 
PF-06882961, administered at 2 PK stead y - state dose levels, on the SD PK of atorvastatin
andmidazolam , administered separately, in healthy  adult male and female participants with a 
BMI rang ingfrom 20.0 kg/m2to <30.0 kg/m2.  
Approximately  16 subjects will be enrolled in Part A.   
The total duration of participation from the Screening Visit ( 28 day s) to the FU contact will 
be approximately  18 weeks; ie, 125 day s, of which 6 4days will be in -house as follows: 
Period 1 (SD atorvastatin): 4 day s; Period 2 (SD mid azolam): 1 day ; Period 3 (BID 
PF-06882961 titrated to 120 mg BID ): 31days; Period 4 (120 mg BID PF-06882961+ SD 
atorvastatin) : 3 day s; Period 5 (120 mg BID PF-06882961 + SD midazolam ): 1day;Period 6
(BID PF-06882961 titrated to 200 mg BID ): 19days;Period 7(200 mg BID PF-06882961+ 
SD atorvastatin) : 3days;Period 8(200 mg BID PF-06882961 + SD midazolam ): 2days
(Table 8).
TheFUvisit will occur 7
-10 day s from the last dose of study  intervention and a FUcontact
will occur 28-35 days from thelast dose ofstudy  intervention .
4.1.2. Part B
Part B of this study is anopen -label, 5-period, fixed -sequence stud y to evaluate the effect of 
PF-
06882961 , administered at 2 PK stead y - state dose levels, on the SD PK ofan OC (LE and 
EE)in health y,PMfemale participants with a BMI rang ingfrom 20.0 kg/m2to <30.0 kg/m2. 
Approximately  16 subjects will be enrolled in Part B.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 42The total duration of participation from the Screening Visit (28 day s) to the FU contact will 
be approximately  18 weeks; ie, 125 day s, of which 67 days will be in -house as follows: 
Period 1 (SD OC): 6 days; Period 2 (BID PF -06882961 titrated to 120 mg BID ): 31days; 
Period 3 (120 mg BID PF-06882961 + SD OC) 5 day s; Period 4 (BID PF -06882961 titrated 
to 200 mg BID )19 day s; Period 5 (200 mg BID PF-06882961+ SD OC) : 6days (Table 9).
The FUvisit will occur 7-10 day s from the last dose of study  intervention and aFUcontact
will occur 28-35 days from thelast dose ofstudy  intervention .
4.2.Scientific Rationale for Study Design
The purpose of this stud y is to characterize the effect of PF -06882961, administered at 
2steady -state dose levels, on the PK of single doses of 
atorvastatin (20mg), midazolam 
(
5mg), and an OC (LE 0.15 mg/EE0.03 mg ), administered separatel y, in healthy  adult 
participants.  
Titration of PF -06882961 doses will be utilized to achieve doses of 120 mg BID and 
200mgBID in Part A and Part B. The DDI effect will be initially  assessed at PF -06882961 
120mgBID and again at 200 mg BID , as these doses are bein g studied in Phase 2 for T2DM 
and obesity . PF-06882961 will be administered for a duration of 7days at each of the 
120
mg BID and 200 mg BID dosing regimens prior to administration of the SD atorvastatin, 
midazolam, orOC treatments in each of the releva nt study  periods in both Parts A
(atorvastatin or midazolam Table 8)and B (OC) Table 9to ensure that clinically  relevant 
steady -state PF -06882961 exposures are achieved and to assess the CYP3A induction
potential of PF -06882961 , should that be a mechanism contributing to an y DDI observations 
in this study .  
4.2.1. Part A
4.2.1.1. Midazolam Administration
Prior publications have demonstrated lower clearance of CYP3A substrates in participants 
with obesity , in addition to alterations in clearance after body  weight loss .14,15,16,17  To 
minimize potential impact of body  weight or weight loss on clearance of CYP3A substrates , 
this study  will enroll participants 
with a BMI rang ingfrom 20.0 kg/m2to <30.0 kg/m2, which 
represents a different study population than that studied in the previously  conducted 
C3421007 study . Additionally , since preliminary  results from study  C3421007 indicate 
possible induction of CYP3A, mida zolam will be used as a “sensitive substrate” of CYP3A 
in this study  to assess the impact of MDPF-06882961 administration on its PK. To further 
investigate the mechanism of this interaction, p lasma 4- -hydroxycholesterol/cholesterol and 
EV samples, used as endogenous probes for CYP3A induction, will be collected and 
analyzed in this study .
Midazolam is rapidly  absorbed after oral administration and is subject to substantial intestinal 
and hepatic first -pass metabolism. Food effect has not been tested using midazolam HCl 
syrup; however, when a 15 mg oral tablet of midazolam was administered with food to 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 43adults, the absorption and disposition of midazolam was not affected. The extent of plasma 
protein binding of midazolam is moderatel y high and concentration independent. In adults 
and pediatric patients older than 1 year, midazolam is approx imately  97% bound to plasma 
protein, principall y albumin. In healthy  volunteers, α -hydroxymidazolam is bound to the 
extent of 89%.13
Midazolam is pr imarily  metabolized in the liver and gut by  human CYP3A4 to its 
pharmacologic active metabolite, α- hydroxymidazolam, followed by glucuronidation of the 
α-hydroxyl metabolite which is present in unconjugated and conjugated forms in human 
plasma. The α -hydroxymidazolam glucuronide is then excreted in urine.  Midazolam is also 
metabolized to 2 other minor metabolites: 4- hydroxy  metabolite (about 3% of the dose) and 
1,4-dihydroxy metabolite (about 1% of the dose) are excreted in small amounts in the urine 
as co njugates.13
Six SDpharmacokinetic studies involving healthy adults yield pharmacokinetic parameters 
for midazolam in the following ranges: volume of distribution, 1 to 3.1 L/kg; elimination 
half-life, 
1.8 to 6.4 hours (mean approximately  3 hours); total clearance, 0.25 to 0.54 L/hr/kg. 
In a study  comparing normals (n=20) and obese patients (n=20) the mean half -lifewas 
greater in the obese group (5.9 hours vs. 2.3 hours), which was attributed to an inc rease of 
approximately  50% in the volume of distribution corrected for total body  weight.13,18,19  
Plasma samples for midazolam and 1 -OH-midazolam will be collected in this study  for up to 
24hours after dosi ng, which is expected to be adequate given the average 2 to 3 hour 
elimination half -life in non- obese subjects. 
Single, oral doses of midazolam ranging from 5 to 7.5 mg have been safel y administered in 
previous internal Pfizer drug-drug interaction studies (A5351012, B3291023, C1061016) , 
and the 5 mg midazolam dose is expected to be well -tolerated in the health y male and female 
participants in this study  as well.
4.2.1.2.
Atorvastatin Administration
Adults with T2DM often require treatment for h yperlipidemia, therefore ,it is likely  that 
PF-06882961 may  be co -administered with atorvastatin in clinical practice. Since 
preliminary  results from study  C3421007 indicate possible induction of CYP3A, atorvastatin 
will be used as a “moderate sensitive substrate” of CYP3A in this study  to assess the impact 
of MDPF-06882961 administration on its PK. 
Atorvastatin is rapidly  absorbed after oral administration; Cmax(plasma) occur swithin 1 to 
2hours.  The absolute bioavailability  of atorvastatin (parent drug) is approx imately  14%.  
The low sy stemic availability  is attributed to presystemic clearance in gastrointestinal 
mucosa and/or hepatic first-pass metabolism.  Food decreases the rate and extent of drug 
absorption by  approximately  25% and 9%, respectively , as assesse d by Cmaxand AUC.  
Plasma atorvastatin concentrations are lower (approximately  30% for C maxand AUC) 
following evening drug administration compared with morning.  Plasma concentrations of 
atorvastatin are higher (approximately  40% for C maxand 30% for AUC ) in healthy  elderl y 
subjects (age ≥65 years) than in y oung adults.13

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 44Atorvastatin is also a substrate of the hepatic transporters, OATP1B1 and OATP1B3.  
Metabolites of atorvastatin are substrates of OATP1B1.  Additionally , atorvastatin is 
identified as a subst rate of the efflux transporter BCRP, which may  limit its intestinal 
absorption and biliary  clearance.13  Intestinal BCRP acts as an efflux transporter limiting 
atorvastatin absorption, while liver BCRP actively  excretes atorvastatin into the bile.  
Asboth in vitro data and preliminary  results from Study  C3421007 indicate that 
PF-06882961 is a BCRP inhibitor , and in vitro data indicate that PF -06882961 may pose a 
potential risk for OATP inhibition at higher doses (200 mg BID) , the current study  may  also 
provide insight into the net 
effect of CYP3A induction and BCRP/OATP inhibition on the 
PK of atorvastatin during MD administration of PF-06882961.
Because t he elimination half -lives of atorvastatin and its ortho- hydroxy lated metabolite range 
from 11 to 18 hours following single doses ,13,20,21plasma will be collected for up to 72hours 
after dosing for determination of PK parameters.  
Atorvastatin is generally  well- tolerated b y health y participants following single, oral, 
ascending doses as high as 80 mg.22  Adverse reactions have usuall y been mild and transien t .  
For more complete information, please refer to the US Package Insert for atorvastatin.13
4.2.1.3. PF-06882961 Administration
A dense PK profile will be collected for PF -06882961 after reaching the target doses of 
PF-06882961 for each DDI assessment; ie, 120 mg BID in Period 3, Day  31 and 200mgBID 
in Period 6, Day 19, to better understand the PK in healthy male and female participants, and 
to allow for PK comparisons with the T2DM and obesity  participants included in studies 
C3421002 and C3421007, respectivel y. 
PF-06882961 will be admin istered via 4- day titration increments up to the 120 mg BID 
regimen in Period 3 prior to the administration of atorvastatin and midazolam in Periods 4 
and 5, respectivel y.  Likewise, PF -06882961 will be administered via 4 -day titration 
increments up to the 200 mg BID regimen in Period 6 prior to administration of atorvastatin 
and midazolam in Periods 7 and 8, respectively (Section 6.1.1, Table 8).  The PF - 06882961 
dosing regimen is designed to achieve and maintain PK steady -state for approximately  7days 
prior to assessment of the interaction with atorvastatin or midazolam.  This will enable an y 
interaction that is present to be assessed under conditions that are expected to increase the 
potential for maximal induction at the PF- 06882961 doses being studied. Based on emerging 
data from other clinical studies that may  become available during the conduct of this study , 
the titration rate, incremental increases in dose, and/or the PF -06882961 doses at which 
atorvastatin and midazolam PKinteractions are evaluated may  be adjusted.  
Dosing of PF -06882961 (with or without atorvastatin or mi dazolam ) is planned to occur in 
the fed state, with standard breakfast and dinner, as this is the anticipated mode of 
administration in clinical use.  Dosing of atorvastatin or midazolam (with or without 
PF-06882961) is planned to occur in the fed state, w ithastandard breakfast .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 454.2.2. Part B
4.2.2.1. Oral Contraceptive Administration
The estrogens and progestins contained in oral contraceptives are substrates for CYP3A4/5 
and other inducible metabolic enzy mes.  Because the anticipated target population for 
PF-06882961 w ill include females of childbearing potential who may  use an OC, a third 
objective of this study  is to estimate the effect of MDadministration of 120 mgBID and 
200mg BID PF -06882961 on the SDPK of an OC containing 0.15 mg LE 
and 0.03 mg EE
in healthy ,PMfemale participants.  
The mean (SD) half -lives of LE and EE are 29.8 (8.3) and 15.4 (3.2) hours,14respectively; 
therefore, plasma will be collected for up to 120 hours after dosing for determination of PK 
parameters. The effect of food on the rate and the extent of LE and EE absorption f ollowing 
oral administration of LE and EE tablets has not been evaluated.14
A dense PK profile will be collected for PF -06882961 after reaching the t arget doses of 
PF-06882961 for each DDI assessment; ie, 120 mg BID in Period 2, Day  31 and 200 mgBID 
in Period 4, Day 19, to better understand the PK in healthy , PM female participants, and to 
allow for PK comparisons with the T2DM and obesity  participant sincluded in studies 
C3421002 and C3421007, respectivel y. 
Oral contraceptive use has been shown to cause an increase in BPthat is reversible when the 
oral contraception is discontinued.  The use of an OC agent containing 30 µg EEand 150 ug 
LE was associated with a small increase in both s ystolic and diastolic BP.23  Although the 
risk of increased BPis expected to be small following SDadministration of the OC in this 
study , BP effects resulting from co -administration of PF -06882961 with the OC will be 
monitored as described below.  For more complete information, please refer to the Package 
Insert for the OC.14
4.2.2.2. PF-06882961 Administration
PF-06882961 will be administered via 4 -day titration increments up to the 120 mg BID 
regimen in Period 2 prior to the administration of the OC Period 3.  L ikewise, PF -06882961 
will be administered via 4- day titration increments up to the 200 mg BID regimen in Period 4 
prior to administration of the OC Period 5 (Section 6.1.1, Table 9).  The PF -06882961 dosing 
regimen is designed to achieve and maintain PK stead y
-state for approximately  7days prior 
to assessment of the interaction with the OC.  This will enable an y interac tion that is present 
to be assessed under conditions that are expected to increase the potential for maximal 
induction at the PF -06882961 doses being studied.  Based on emerging data from other 
clinical studies that may  become available during the conduct of this study , the titration rate, 
incremental increases in dose, and/or the PF -06882961 doses at which the OC ( LE/EE ) PK
interactions areevaluated may  be adjusted.  
Dosing of PF -06882961 (with or without OC) is planned to occur in the fed state, with 
standard breakfast and dinner, as this is the anticipated mode of administration in clinical use.  
Dosing of theOC(with or without PF -06882961) is planned to occur in the fed state, with a 
standard breakfast .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 464.2.3. Parts A and B Safety Assessments 
Clinical labo ratory  tests, assessments of vital signs, body weight, and 12- lead ECGs, phy sical 
examinations, and AE monitoring will provide data to evaluate the safet y and tolerability of 
PF-06882961.  Vital signs will be monitored at frequent intervals, as both increa ses in HR 
and mild decreases in s ystolic BP have been observed with PF
-06882961 administration.  
Body weight will be measured at timepoints in the SoA, as GL P-1R agonists have been 
shown to decrease food intake and bod y weight.  COVID -19 specific assessments have been 
incorporated to minimize the risks of COVID -19 related complications to participants and the 
study  site personnel.
As part of the clinical safety  laboratory  tests, fasting blood glucose and HbA1c, will be used 
to ass ess changes in gl ycemic parameters in this study  population.  In addition, calcitonin, 
amylase, and lipase will be assessed, as these laboratory  parameters have been shown to 
increase with marketed GL P-1R agonists.24-26  In addition, TSH, free T4, lipids, coagulation 
profile and TBA will be assessed, based on non- adverse findings in the nonclinical studies 
with PF -06882961.  Assessment of SIBby C-SSRS27and PHQ -928will also be performed 
based on the potential risk related to the product labeling for the injectable GL P-1R agonist 
liraglutide in patients with BMI ≥30 kg/m2.29
While GL P-1R agonists ty pically  are not associated with hy poglycemia unless 
co-administered with anti -diabetic agents that can cause h ypogl ycemia (such as insulin or 
sulfony lureas), blood glucose concentrations will be monitored throughout the study  via 
laboratory  assessments, and monitoring of s ymptomatic HAEs will be performed.  In 
addition, all participants will be instructed regarding the s ymptoms associated with, and 
management of, h ypogl ycemia, which will permit the monitoring of s ymptomatic HAEs.
In Part A of this study , WOCBP may be enrolled given the availability  of embry o fetal 
developmental toxicity  studies with PF -06882961.  However, as m arketed GL P-1R agonists, 
in addition to ator vastatin, are listed as contraindicated in pregnancy , the use of a highl y 
effective method of contraception is required and measures will be taken to limit the risk of 
pregnancy  in the female population enrolled (see SoA and Appendix 4 ).
The potential risk of exposure to PF- 06882961 in a sexual partner of a male participant in 
this study  via ejaculate is low, and therefore no contraception (con dom) use in male 
participants is warranted.  The calculated safet y margin is ≥100 fold between the estimated 
partner exposure due to seminal transfer and the NOAEL for serious manifestations of 
developmental toxicity  in nonclinical studies.  The safet y mar gin of 100 -fold is based on 
apply ing a 10 -fold safet y factor for interspecies extrapolation and a 10 -fold safet y factor for 
susceptible populations.30
4.2.4. Diversity of Study Population  
Not applicable.

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 474.2.5. Choice of Contraception/Barrier Requirements 
Human reproductive safety data are limited for PF-06882961, but there is no suspicion of 
human teratogenicity based on the completed nonclinical embryo-fetal developmental studies.  Therefore, the use of a highly effective method of contraception is required for Part A only (see Appendix 4 ).  
 
4.3. Justification for Dose
PF-06882961:
The DDI assessment will occur at 2 PK steady-state PF-06882961 dose levels, 120 mg BID 
and 200 mg BID.  These doses represent the highest doses being assessed in the Phase 2studies for T2DM and obesity. The 120 mg BID and 200 mg BID doses were also administered in the Phase 1 midazolam and rosuvastatin DDI study (C3421007) and will, therefore, allow DDI assessment in this study at an anticipated exposure that was sufficiently tolerated.  Exposure margins for PF-06882961 120 mg BID and 200 mg BID are given inSection 2.2.3 . 
The titration to PF-06882961 120 mg BID is planned to occur over an approximately 24-day 
period, and from 120 mg to 200 mg BID over 12 days, in increments of 20 mg every 4 days(Section 6.1.1 , Table 8 and Table 9 ).  These titration increments have been administered
previously in Study C3421007 and were sufficiently tolerated.  Based on emerging data from other clinical studies that may become available during the conduct of this study, the titration rate, incremental increases in dose, and/or the PF-06882961 doses at which atorvastatin, midazolam or the OC PK interactions are evaluated may be adjusted.  
Atorvastatin:In a SD escalation study, atorvastatin was safe and well tolerated at doses up to 80 mg.  The 
only adverse event that occurred in more than 2 participants per treatment was headache. All episodes were of mild or moderate intensity. Other drug-related side effects included sporadic reports of diarrhea, flatulence, and nausea. There was no clear relationship between atorvastatin dose and the frequency or intensity of AEs. No SAEs were reported.
22
The dose range for atorvastatin in clinical practice is 10 to 80 mg QD, with recommended starting doses of 10 or 20 mg QD.
13  Since it is unknown whether PF-06882961 will decrease 
or increase atorvastatin plasma exposure in this study, 20 mg atorvastatin was selected as the dose.  This dose should allow for adequate quantification of atorvastatin and its ortho-hydroxy lated metabolite in plasma should the net result of PF-06682961 
co-administration be CYP3A induction.  CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 48Furthermore, a 20 mg dose of atorvastatin is expected to be well -tolerated should sy stemic 
exposures increase due to net BCRP/OATP inhibition.  Although atorvastatin is a substrate 
for the BCRP, OATP1B1, and OATP1B3 transporters, and PF-0682961 was shown to inhibit 
BCRP as evidenced b y the increased ros uvastatin exposures observed in Study  3421007, the 
20mg dose is expected 
to be safe .  Maximal increases for rosuvastatin AUC and C maxin 
Study  C342 1007 were approximately  2.6-foldand 4.4 -fold, respectivel y, at the 200 mgBID 
dose of PF -
06882961.  Since rosuvastatin is a more sensitive BCRP substrate than 
atorvastatin, any increases in exposure observed for atorva statin due to BCRP inhibition in 
the current study  are not expected to be a greater than 4- fold .  Furthermore, in vitro data do 
not indicate a potential for inhibition of OATP1B1 by PF-06882961, and only  weak 
inhibition of OATP1B3 at 200 mg BID PF-06882961 . Finally , based on the midazolam
results 
from Study  3421007 ,some degree of CYP3A induction is likely  such thatthenet 
result of transporter inhibition and enzy me induction is not expected to result in atorva statin
exposures that exceed that of a single 80 mg dose, which is a clinicall y prescribed dose.
Midazolam:
Midazolam has been administered at doses of 2 -15 mg to assess CYP3A4/5 DDI s31and was 
well tolerated at a dose of 2 mg in S tudy C3421007 .  Likewise , a single ,oral 5mg dose of 
midazolam in this study should allow for adequate quantification of midazolam and its 
1-OH-metabolite in plasma for 24 hours and is expected to be well- tolerated .
LE/EE:
The OC selected for this study  contains a fixed dose of 0.15 mg LEand 0.03 mg EE.  The 
amounts of estrogen and progestin in this preparation are comparable to those found in man y 
of the commonly  prescrib ed OCs, and have been used in a number of published OC 
drug-
drug interaction studies with other CYP3A inducers, such as phen ytoin and
carbamazepine.32
Doses presented are projected based on the available clinical data , but may be modified 
based on emerging safet y, tolerability ,and/orPK data.
4.4.End of Study Definition
A participant is considered to have completed the study  if he/she has completed all phases of 
the study , including the FUcontact visit, approximately  28 to 35 days post last dose of study  
intervention.
The end of the st udy is defined as the date of the last visit ( FUcontact) of the last participant 
in the study .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 495.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled. The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective 
approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Ageand Sex :
1.Part A Only  -Healthy  male and female participants must be 18 to 65 years of age, 
inclusive ,at the time of signing the ICD (healthy  is defined as no clinically  relevant 
abnormalities identified by  a detailed medical history , phy sical examination, 
including blood pressure and pulse rate measurement, standard 12 -lead ECG and 
clinical laboratory  tests).
Women can be of child -bearing potential, however, cannot be pregnant, 
breastfeeding, or planning to become pregnant while participating i n the study and 
may not be taking oral contraceptives.
Refer to Appendix 4for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participants.
2.Part B Onl y -Healthy  PM female participants between 40 and 65 years of age, 
inclusive ,at the time of signing the ICD (healthy  is defined as no clinically  relevant 
abnormalities identified by  a detailed medical history , phy sical examination, 
including BP and PR measurement, standard 12- lead ECG and clinical laboratory  
tests).  Subjects must be amenorrheic for at least 12 months.  Women who are 
60years of age or younger must also have an FSH that is within the laboratory’s 
reference range for PM women.
Type of Participant and Disease Cha
racteristics:
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
Weight:
4.BMI -20.0 kg/m2to <30.0 kg/m2at Screening. 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 505.Stable body weight, defin ed as <5 %change (per participant report) for 90 days 
before Screening. 
Informed Consent:
6.Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictio ns listed in the I CDand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy chiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
2.Any condition possibly  affecting drug absorption (eg, pri or bariatric surgery , 
gastrectom y, or an y area of intestinal resection, active inflammatory  bowel disease or 
pancreatic insufficiency ). 
3.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk 
of study participation or, in the investigator’s judgment, make the participant 
inappropriate for the study .
4.Known intolerance or h ypersensitivity  to GLP -1R agonists.
5.Known hy persensitivity  to atorvastatin or midazolam (for participants in Part A)
, or 
LE and EE (for participants in Part B) .
6.Personal or famil y history of MTC or MEN2 or study  participants with suspected 
MTC per the investigator’s judgment.
7.Symptomatic gallbladder disease.
8.History  of major depr essive disorder or history  of other severe ps ychiatric disorders 
(eg,schizophrenia or bipolar disorder) within the last 2 years from screening.
9.Any lifetime history  of a suicide attempt.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 51Prior/Concomitant Therapy:
10.Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention .  (Refer to Section 6.8 Concomitant Therap y for additional details ).
11.Systemic therapy  with any  of the medications that are moderate or strong CYP3A4/5, 
CYP2C9 and/or CYP2C19 inhibitors within 28 day s or 5 half -lives (whichever is 
longer) or moderate or strong CYP3A, CYP2C9 and/or CYP2C19 inducers within 
28days or 5 half -lives (whichever is longer) prior to the first dose of study  
intervention (Refer to Section 6.8 for additional details). 
12.Systemic therapy  with inhibitors of the BCRP transporter within 28 days or 
5half-
lives (whichever is longer) prior to the first dose of study  intervention .(Refer 
toSection 6.8 for additional details). 
13.Current use of an
y prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to Section 6.8Concomitant 
Therap y.
Prior/Concurrent Clinical Study Experience:
14.Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or 5half-lives preceding the first dose of study  intervention
used in this study (whichever is longer). 
15.Known prior participation in a trial i nvolving PF -06882961.
Diagnostic Assessments:
16.A PHQ -9 score ≥ 15 obtained at Screening or Day  -1 in Study .
17.Response of “yes” to question 4 or 5, or on any  suicidal behavioral question on the 
C
-SSRS at Screening or Day  -1 in Study .
18.A positive urine drug tes
t. 
19.Screening supine BP ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least 5 minutes of supine rest.  BP should be measured in triplicate and the average of 
the 3 BP values should be used to determine the participant’s eligibility .  Note: A t 
screening, the participant’s arm circumference should be measured (eg, using a 
flexible anthropometric tape) at the midpoint of the length of the upper arm and the 
appropriate cuff selected and used throughout the study .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 5220.Screening 12- lead ECG that demonstrates clinically  relevant abnormalities that may  
affect participant safet y or interpretation of stud y results (eg, QTcF interval 
>450 msec, complete LBBB, signs of an acute or indeterminate age -myocardial 
infarction, ST -T interval changes suggestive of myo cardial ischemia, second or -third 
degree AV block, or serious brad yarrh ythmias or tachy arrhy thmias).  
If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 
2
more times and the average of the 3 QTcF or QRS values should be used to 
determine the participant’s eligibility .  Computer interpreted ECGs should be 
overread b y a ph ysician experienced in reading ECGs before excluding participants.
21.Participants with ANY of the following abnormalities in clinical laboratory  tests at 
Screeni ng, as assessed b y the study  specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary :
HbA1c ≥6.5%.
Aspartate 
AST or ALT level ≥2times the ULN.
Total bilirubin level ≥1.5 times the UL N; participants with a history  of Gilbert's 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is ≤ ULN.
TSH >1.5
x the UL N or <LLN.
Serum calcitonin > the ULN.
Amy lase or lipase > the ULN.
Fasting blood glucose ≥126 mg/dL. 
Fasting C -peptid e <0.8 ng/mL.
eGFR <70mL/min/1.73 m2as calculated b y the CKD -EPI equation.
Positive testing for HIV, HepBsAg, or HCVAb.  Study  participants positive for 
HCVAb are to be excluded unless known to have been treated with a known 
curative therap y and negative for HCV RNA.  Hepatitis B vaccination is allowed.
A positive SARS -CoV -2test.
Other Exclusions :at Screening unless indicated
22.Participation in a formal weight reduction program (eg, Weight Watchers) within 
90days prior to Screening.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 5323.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening.  Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours.  As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit= 8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
24.Current use of tobacco or nicotine containing products in excess of the equivalent of 
5cigarettes per day .
25.Known or suspected illicit drug use.
26.Blood donation (excluding plasma donations) of approximately  1pint (500 mL) or 
more within 60 days prior to dosing randomization (Day -1). 
27.History  of sensitivity  to heparin or heparin induced thrombocy topenia if Hep- lock is 
used for IV blood draw.
28.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol.
29.Investigator site staff or Pfizer employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  the investigator, and their respective family  
members. 
5.3.Lifestyle Considerations
The following g uidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participants must abstain from all food and drink (except water) for at least 8 hours 
prior to an y safety laboratory and the morning predose PK evaluations (Periods 1-8in 
PartA and Periods 1
-5 in Par t B).
Water may  be consumed as desired (ad libitum).
Participants should begin consumption of a standard breakfast (morning) and evening 
meal approximately  30 minutes prior to dosing.  The breakfast and evening meal 
(dinner) will be consumed over approxima tely a 20 minute period, with the study  
intervention (PF -06882961) administered within approximately  10 minutes of 
completion of the meal.  Participants will be encouraged to complete the entire meal.
Study  intervention (PF -06882961) must be administered BID approximately  10hours 
apart. 
Atorvastatin , midazolam or OCwhen administered alone will be given within 
approximately  10minutes of completion of the morning meal. 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 54PF-06882961 will be administered first and the single dose of atorvastatin , 
midazolam or the OC will be administered within 5 minutes of PF -06882961 for the 
periods in which atorvastatin , midazolam, or the OCare co -administered with 
PF-06882961. 
Noncaffeinated drinks (except red wine, grapefruit or grapefruit -related citrus fruit 
juices —see below) may  be consumed with meals and the evening snack .  
Lunch will be provided approximately  4hours after dosing with study  intervention 
(PF-06882961).  This applies to atorvastatin , midazolam andthe OC also.
Dinner will be provided approximately  10hours after dosing with study  intervention. 
This applies to atorvastatin, midazolam and the OC also.
An evening snack may  be permitted.
Participants will refrain from consuming red wine, grapefruit, or grapefruit related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 day s prior to Period 1 
Day 1 until collection of the final PK blood sample inPart A, Period 8, Day 2 or 
PartB, Period 5, Day  6.  
While participants are confined, their total daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein.  The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.2. Caffeine, Alcohol, and Tobacco
Tobacco or nicotine use may  be allowed according to CRU practices.  Tobacco or 
nicotine use will not be permitted during frequent sampling procedures, and will not 
be permitted within 2 hours prior to an y vital sign or ECG assessments.  Tobacco or 
nicotine use will also not be permitted 2 hours before and 2 hours following an y dose 
of study intervention.  
Caffeine containing products will be permitted during the stud y with the following 
restrictions: caffeine containing products may  not be consumed within 1 hour prior to 
measuring vital signs and ECGs.
Participants will abstain from alcohol for 24 hours prior to admission to the CRU and 
continue abstaining from alcohol until collection of the final PK sample i
n Part A, 
Period 8, Day 2 or Part B, Period 5, Day  6.  Participants may  undergo an alcohol 
breat h test or blood alcohol test at the discretion of the investigator.  
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests.  Walking at a normal pace will be permitted.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 55In order to standardize the conditions on PK sampling day s, participants will be 
required to refrain from ly ing down for 4 hours after dosing in the morning on day s of 
post-dose PK sample colle ctions (except when required for BP, pulse rate, and ECG 
measurements).
5.3.4. Contraception
Part A
WOCBP Only  - The investigator or his or her designee, in consultation with the participant, 
will confirm that the participant has selected an appropriate method of contraception for the 
individual participant and his or her partner(s) from the permitted list of contraception 
methods (see Appendix 4) and will confirm that the participant has been instructed in its 
consi stent and correct use.  At time points indicated in the schedule of activities (SoA) , the 
investigator or designee will inform the participant of the need to use highly  effective 
contraception consistently and correctl y and document the conversation and the participant’s 
affirmation in the participant’s chart (participants need to affirm their consistent and correct 
use of at least 1 of the selected methods of contraception) considering that their risk for 
pregnancy  may  have changed s ince the last visit .  In addition, the investigator or designee 
will instruct the participant to call immediately  if the selected contraception method is 
discontinued or if pregnancy  is known or suspected in the participant or partner.
Part B
Not applicable. 
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  dosed in the study .  Screen failure data are collected and remain as 
source and are not reported to the c linical database.
A participant who qualified for this protocol but did not enroll within the 28 -day screening 
window may  be re -screened. In this situation, all screening procedures must be repeated and 
the participant assigned a new 8- digit(SSI D number. This criterion would also apply  to 
participants who screened for this study  more than 28 days prior to dosing.
6.STUDY INTERVENTION (S) AND CONCOMITANT THERAPY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF-06882961.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 566.1.Study Intervention(s) Administered
10 mg, 40 mg, and 100 mg PF -06882961 tablets will be supplied by  Pfizer to the CRU in 
bulk along with individual dosing containers, as necessary , for unit dosing.
Commercially  available midazolam oral sy rup (2 mg/mL) will be supplied by  the CRU. 
Commercially  available oral atorvastatin 20 mg tablets will be supplied by  the CRU.
Commercially  available OC tablets
(LE 0.15 mg/EE 0.03 mg ) will be supplied by  the CRU. 
6.1.1. Administration
Participants will receive PF -06882961 (morning dose), atorvastatin , midazolam or OCas 
applicable per the SoA at approximately  0800 hours ( ±2 hours).  Participants will receive the 
evening dose of PF -06882961 approximately  10 hours after the morning dose of 
PF-06882961. Details on meals and dietary  requirements and activity  restrictions on dosing 
days are given in Section 5.3.  
Investigator site personnel will administer PF -
06882961, atorvastatin , midazolam or the OC 
during each period (as applicable per SoA) with ambient temperature water to a total volume 
of approximately  240 mL. Participants will swallo w the study  intervention whole, and will 
not manipulate or chew the study  intervention prior to swallowing .
Administration of study  intervention will occur according to the following Dosing Periods 
and Dosing Day s, also listed in the SoA and Table 8.
Modification of dosing of PF
-06882961 may be permitted upon Sponsor approval only. See
Section 6.5. 
Table 8. Part ADosing
Study Period Days in Study Drug and Dosage
Period 1, Days 1 -3 1 SD Atorvastatin
Period 2, Days 1 4 SD Midazolam
Period 3, Days 1 -4 5-8 PF-06882961 10 mg BID
Period 3, Days 5 -8 9-12 PF-06882961 20 mg BID
Period 3, Days 9 -12 13-16 PF-06882961 40 mg BID
Period 3, Days 13 -16 17-20 PF-06882961 60 mg BID
Period 3, Days 17 -20 21-24 PF-06882961 80 mg BID
Period 3, Days 21-24 25-28 PF-06882961 100 mg BID
Period 3, Days 25 -31 29-35 PF-06882961 120 mg BID
Period 4, Day 1 36 PF-06882961 120 mg BID+ SD Atorvastatin
Period 4, Days 2 -3 37-38 PF-06882961 120 mg BID
Period 5, Day 1 39 PF-06882961 120 mg BID+ SD Midazolam
Period 6, Days 1 -4 40-43 PF-06882961 140 mg BID
Period 6, Days 5 -8 44-47 PF-06882961 160 mg BID
Period 6, Days 9 -12 48-51 PF-06882961 180 mg BID
Period 6, Days 13 -19 52-58 PF-06882961 200 mg BID
Period 7, Day 1 59 PF-06882961 200 mg BID+ SD Atorvastatin

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 57Study Period Days in Study Drug and Dosage
Period 7, Days 2 -3 60-61 PF-06882961 200 mg BID
Period 8, Day s1-2 62-63* PF-06882961 200 mg BID+ SD Midazolam
* There is no PF -06882961 administration on Day 6 3.
Table 9. Part B Dosing
Study Period Days in Study Drug and Dosage
Period 1, Days 1 -5 1 SD OC
Period 2, Days 1 -4 6-9 PF-06882961 10 mg BID
Period 2, Days 5 -8 10-13 PF-06882961 20 mg BID
Period 2, Days 9 -12 14-17 PF-06882961 40 mg BID
Period 2, Days 13 -16 18-21 PF-06882961 60 mg BID
Period 2, Days 17-20 22-25 PF-06882961 80 mg BID
Period 2, Days 21 -24 26-29 PF-06882961 100 mg BID
Period 2, Days 25 -31 30-36 PF-06882961 120 mg BID
Period 3, Day 1 37 PF-06882961 120 mg BID+ SD OC
Period 3, Days 2 -5 38-41 PF-06882961 120 mg BID
Period 4, Days 1 -4 42-45 PF-06882961 140 mg BID
Period 4, Days 5 -8 46-49 PF-06882961 160 mg BID
Period 4, Days 9 -12 50-53 PF-06882961 180 mg BID
Period 4, Days 13 -19 54-60 PF-06882961 200 mg BID
Period 5, Day 1 61 PF-06882961 200 mg BID+ SD OC
Period 5, Days 2 -6 62-66* PF-06882961 200 mg BID
* There is no PF -06882961 administration on Day 66 .
Following an overnight fast of at least 10 hours , participant s will receive study  intervention
at approximately  0800 hours ( ±2hours). Investigator site personnel will administer study  
intervention during each period with ambient temperature water to a total volume of 
approximately  240 mL. Participant s will swallow the study  intervention whole, and will not 
manipulate or chew the study  intervention prior to swallowing. The study  intervention will 
be administered according to the IP manual.
In order to standardize the conditions on PKsampling day s, all participant s will be required 
to refrain from ly ing down (except when required for 
BP, PR, and ECG measurements), 
eating, and drinking beverages other than water during the first 4 hours after dosing.
6.2.Preparation , Handling , Storage , and Accountability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been ma intained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply or administer study  intervention. All study 
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investig ator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 58must be documented and available upon request. Data for nonworking days must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon return to business.
3.Any excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer provides permission 
to use the study  intervent ion. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the IP manual .
4.Any storage conditions stated in the SRSD will be superseded b y the storage 
conditions stated on the label.
5.Study  interventions should be stored in their original containers.
6.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y interven tion accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study  intervention accountabil ity form/record.
7.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, t he 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y Pfizer.
Upon identification of a product complaint, notify the sponsor w ithin 1 business day  of 
discovery as described in the I P manual.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by  qualified 
staff.  Dispensing is defined as the provision of study intervention, concomitant treatments, 
and accompan ying information by  qualified staff member(s) to a healthcare provider, 
participant in accordance with this protocol.  L ocal health authority  regulations or 
investigator site guidelines may  use alternative terms for these activities.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 59Tablets will be prepared at the CRU in the individual dosing containers b y 2operators, 1 of 
whom is an appropriatel y qualified and experienced member of the stud y staff (eg, ph ysician, 
nurse, ph ysician’s assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist).  
The tablets will be provided in unit dose containers and labeled in accordance with Pfizer 
regulations and the clinical site’s labeling requirements. 
Commercially  available products atorvastatin , midazolam and the OC provided by  the CRU 
will be prepared as per the label and in accordance with the Protocol by  2 operators, 1 of 
whom is an appropriatel y qualified and experie nced member of the study  staff.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
This is a non- randomized, open -label stud y.  The investigator’s knowledge of the treatment 
should not influence the decision to enroll a particular participant or affect the order in which 
participants are enrolled.
The investigator will assign participant numbers to the participants as they  are screened for 
the study .  The first four digits of the SSID will reflect the sponsor- assigned sit e number and 
the remaining four -digits will reflect each participant ’s unique number assigned in 
chronological order as informed consent is obtained. In addition
,on Day  1of Period 1, each 
participant who is dosed with the investigational product will be assigned a separate, distinct 
number (as provided to the site by  the Sponsor at the start of the study ) to enable execution of 
Sponsors ’standard processes for analy sis of all PK -
related samples.
In Part A ( Periods 3 to 8 ) and Part B (Periods 2 to5, participants will receive the 
PF-06882961 doses as described in Table 10.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 60Table 10. PF-06882961 Dosing Regimens Part A
Period & 
PF-06882961 Dose 
(dosed twice daily)Number of PF -06882961 Tablets Total Number of 
Tablets10mg 40mg 100mg
Period 3: 10 mg 1 - - 1
Period 3: 20 mg 2 - - 2
Period 3: 40 mg - 1 - 1
Period 3: 60 mg 2 1 - 3
Period 3: 80 mg - 2 - 2
Period 3: 100 mg - - 1 1
Period 3: 120 mg 2 - 1 3
Period 4: 120 mg 2 - 1 3
Period 5: 120 mg 2 - 1 3
Period 6: 140 mg - 1 1 2
Period 6: 160 mg 2 1 1 4
Period 6: 180 mg - 2 1 3
Period 6: 200 mg - - 2 2
Period 7: 200 mg - - 2 2
Period 8: 200 mg - - 2 2
PF-06882961 Dosing Regimens Part B
Period & 
PF-06882961 Dose 
(dosed twice daily)Number of PF -06882961 Tablets Total Number of 
Tablets10mg 40mg 100mg
Period 2 : 10 mg 1 - - 1
Period 2 : 20 mg 2 - - 2
Period 2 : 40 mg - 1 - 1
Period 2 : 60 mg 2 1 - 3
Period 2 : 80mg - 2 - 2
Period 2 : 100 mg - - 1 1
Period 2 : 120 mg 2 - 1 3
Period 3 : 120 mg 2 - 1 3
Period 3 : 120 mg 2 - 1 3
Period 4 : 140 mg - 1 1 2
Period 4 : 160 mg 2 1 1 4
Period 4 : 180 mg - 2 1 3
Period 4 : 200 mg - - 2 2
Period 5 : 200 mg - - 2 2
Period 5 : 200 mg - - 2 2
Study  intervention will be dispensed at the stud y visits as summarized in the SoA. Returned 
study  intervention must not be redispensed to the participants.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 616.4. Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply , the preparation of 
the dose will be confirmed by  a second qualified member of the study  site staff.
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, u nder medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.  
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dos ing b y a member of the stud y site staff other than the person administering the 
study  intervention.  Study  site personnel will examine each participant’s mouth to ensure that 
the study  intervention was ingested.
6.5. Dose Modification
If participants are not a ble to tolerate titration to higher doses of PF- 06882961 
(eg, ≥160 mg BID), titration to the next dose level may be delay ed temporarily  or titration to 
a maximum tolerated dose may  be permitted, with Sponsor approval only.
6.6.Continued Access to Study Intervention A fter the End of the Study
No intervention will be provided to study  participants at the end of their study participation .
6.7.Treatment of Overdose
For this study , any  dose of PF -06882961 greater than 600 mg within a 24 -hour time period 
will be considered an overdose. 
For this study , overdose for atorvastatin ,13midazolam15and the OC16will be per the USPI 
label.
There is no specific treatment for an overdose for PF -06882961.  Treatment of overdose
should consist of general supportive measures.
In the event of an overdose, the investigator should:
1.Contact the medical monitor within 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF -06882961 (whichever 
is longer). 
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Safety  only when associated with an SAE .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 625.Obtain a blood sample for PK anal ysis within 1 day  from the date of the last dose of 
study  intervention if requested by  the medical monitor (determined on a case -by-case 
basis).  
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consul tation with the medical monitor based on the clinical evaluation of the participant.
6.8.Concomitant Therapy
Study  participants will abstain from all concomitant treatments, except for the treatment of 
AEs, as described in the Exclusion Criteria sections of this protocol.
Use of prescription or nonprescription drugs and dietary  and herbal supplements
(eg,St.John’s wort) are prohibited within 7 days or 5 half-lives (whichever is longer) prior to 
the first dose of stud y intervention.  Systemic therapy with an y of the medications that are 
moderate or strong CYP3A4/5, CYP2C9 and/or CYP2C19 inhibitors within 28 day s or 
5half-lives (whichever is longer) or moderate or strong CYP3A, CYP2C9 and/or CYP2C19 
inducers within 28 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention .
Hormonal contraceptives are not allowed to be used in participants who are WOCBP (see
Appendix 4 ).
Females using hormonal contraceptives or taking hormone replacement therap y may be 
eligible to participate in this study  if they  are willing to discontinue therapy at least 28 days 
prior to the first dose of study  treatment and remain off hormonal therap y for the duration of 
the study .  Depo- Provera®must be discontinued at least 6 months prior to the first dose of 
study  treatment.
Systemic therapy  with inhibitors of the BCRP or OATP transporter swithin 28 days or 
5half-lives (whichever is longer) prior to the first dose of study  intervention .
Limited use of nonprescription medications that are not believed to affect participant safety  
or the overall results of the study  may  be permitted on a case -by-case basis follo wing 
approval b y the sponsor.  Acetaminophen/paracetamol may be used at doses of ≤1g/day .
Anti- emetics (eg, prochlorperazine, promethazine, ondansetron) may  be administered at the 
investigator’s discretion with notification to the sponsor and entry  in the CRF (See 
Section 6.8.1.1).
Sites are encouraged to contact the sponsor should there be questions as to whether a 
medication is permit
ted or prohibited.
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration.  All participants will be questioned about 
concomitant treatment as listed in the SoA.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 63Treatments taken within 28 days before the first dose of study  intervention will be 
documented as a prior treatment.  Treatments taken after the first dose of study  intervention 
will be documented as concomitant treatments.
6.8.1. Rescue Medicine
There is no rescue therapy  to reverse the AEs observed with PF -06882961; standard medical 
supportive care must be provided to manage the AEs , including administration of 
carboh ydrates to treat HAE s(see Section 8.2.6).
6.8.1.1. Management of Nausea and Vomiting
Nausea and vomiting have been reported with administration of GL P
-1R agonists and also 
with administration of PF -06882961 ( seeSection 2.2.4).  Study  participants complaining of 
nausea may  be managed conservati vely with bed rest and/or fluid management at t he 
discretion of the investigator.  If the nausea and vomiting are not amenable to conservative 
management, anti emetics (eg, prochlorperazine, promethazine, ondansetron) may be 
administered at the investigator’s discretion with notification to the sponsor and entry  in the 
CRF .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention 
(definitive discontinuation).   Reasons for definitive discontinuation of study  intervention 
include the following:
Criteria for a potential Hy ’s law case are met ( see Appendix 6 ).
Intent to become pregnant or pregnancy  confirmed by  serum beta huma n chorionic 
gonadotropin ( -hCG) testing.  
Safety  or tolerabilit y concern arises, in particular if not responsive to s ymptomatic 
management, dosing with study  intervention may  be stopped in an individual 
participant at investigator discretion;  
Based on mental health assessment as 
outlined in Section 8.2.9, should be 
discontinued from dosing at investigator discretion.
If the criteria for permanent discontinuation are met, the site should notify  the sponsor 
Medical Monitor or sponsor Clinician.
Positive 
SARS -CoV -2Test.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 64Note that discontinuation of study  intervention does not represent withdrawal from the study .  
If study  intervention is definitively  discontinued, the participant will remain in the study  to 
be evaluated for ET visit.   See the SoA for data to be collected at the time of discontinuation 
of study  intervention and follow -up for an y further evaluations that need to be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -
up, 
and/or future collection of additional information.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request.  Reasons for 
discontinuation from the study  include the following:
Refused further follow -up.
Lost to follow -up.
Death .
Study  terminated by  sponsor .
Safety  or behavioral r easons at the discretion of the investigator, including reasons 
related to mental health assessments .
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted.  See the SoA for asse ssments to be collected at the time of study  
discontinuation and follow
-up and for an y further evaluations that need to be completed. 
The early discontinuation visit applies only  to participants who are enrolled/randomized and 
then are prematurely  withdra wn from the study .  Participants should be questioned regarding 
their reason for withdrawal.  
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent ( seeSection 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no
additional data should be collected.  The sponsor may  retain and continue to use any  data 
collected bef
ore such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/ ETprocedures will not be viewed as 
protocol deviations so long as the participant’s safety  was preser ved.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 657.2.1. Withdrawal of Consent
Participant s who request to discontinue rec eipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or pe rsons previously  authorized by  the participant to provide this 
information. Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow
-up, whenever possible. The withdrawal of consent 
should be explained in detail in the medical records by  the investigator, as to whether the 
withdrawal is only  from further receipt of study  intervention or also from study  procedures 
and/or posttreatment study  follow -up, and entered on the appropriate CRF page. In the event 
that vital status (whether the participant is alive or dead) is being measured, publicly  
available information should be used to determine vital status only  as appropriately  directed 
in accordance with local law.
7.3.Lost to Fol lowup 
A participa nt will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the stu dy;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailin g 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA.  Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 66Adherence to the stud y desig n requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria.  The in vestigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study .
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant.  When a protocol- required test ca nnot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of th ese incidents in a timely  manner.
If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter. 
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participants in this study  is approximately
350 m L in Part A and 675 mL in Part B .  In Part B of the stud y, the total blood volume taken 
does not exceed 550 mL in any  given 60 -day consecutive period of time.  The actual 
collection times of blood sampling may  change.  Additional blood samples may  be taken for 
safet y assessments at times specified b y Pfizer, provided the total volume taken during the 
study  does not exceed 550 mL during an y period of 60 consecutive day s.
To prepare for stud y participation, participant s will be instructed on the information i n the 
Lifesty le Considerations andConcomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
Not applicable.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled cl inical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 678.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examina tions, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respiratory  and cardiovascular s ystems, and participant -reported s ymptoms.
Complete physical exam will be done at time points specified in the SoA otherwise, brief 
exam if findings during previous exam or new/open AEs, if appropriate, at investigator 
discretion.
Physical examinations may  be conducted by  aphysician, trained phy sician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA.  Height will be 
measured at screening only .  Weight w ill be recorded using a calibrated scale (with the same 
scale used if possible for the duration of the stud y) reporting weight in either pounds (lb) or 
kilograms (kg), and accuracy  to the nearest 0.2 lb (or 0.1 kg); ie, the device must be able to 
distingui sh a difference between 150.4 lb (68.4 kg) versus 150.2 lb (68.3 kg).  The scale must 
be placed on a stable, flat surface. 
Weight measurement should be taken under the following conditions:
In the morning in a fasting state.
After void of urine.
After removal of shoes, bulky  layers of clothing and jackets so that only  light clothing 
remains.
Remove the contents of their pockets. 
While remaining still during the measurement.
Height and weight will also be measured and recorded as per the SoA. For measuring 
weight, a scale with appropriate range and resolution is used and must be placed on a stable, 
flat surface. Participant s must remove shoes, bulky  layers of clothing, and jackets so that 
only light clothing remains. They  must a lso remove the contents of their pockets and remain 
still during measurement of weight. 
Physical examination findings collected during the study  will be considered source data and 
will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Section 8.3.1 to 8.3.3.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 688.2.2. Vital Signs
Vital signs (s ystolic BP, diastolic BP and PR) will occur as specified in the SoA.  Supine BP
will be measured with the participant ’s arm supported at the level of the heart, and recorded 
to the nearest mm Hgafter approximately  5minutes of supine rest .  The same arm 
(preferabl y the dominant arm) will be used throughout the study
.  Participant s should be 
instructed not to speak during measurements .  When triplicate measurements are obtained, 
they should be collected approximately  2minutes apart. 
At Screening, the participant’s arm circumference should be measured (eg, using a flexible 
anthropometric tape) at the midpoint of the length of the upper arm and the appropriate cuff 
selected and used throughout the study .  The same properl y sized and calibrate d BP cuff will 
be used to measure BP each time.  
The use of an automated device for measuring BP and PRis acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery
 for at least 
30seconds.  When the timing of the se measurements coincides with a blood collection, BP 
and PRshould be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BPand PRwill be permitted, 
as necessary , to ensure appro priate collection of safet y data.
8.2.2.1. Temperature
Body temperature will be measured at the timepoints listed in the SoA.  Temperature will be 
measured orally . 
No eating, drinking, or smoking is allowed for 15 minutes prior to the 
measurement.
8.2.3. Electrocardiograms
Standard 12- lead E CGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the HRand measures PR, QT, and QTc Fintervals and QRS 
complex .  Alternative lead placement methodology using torso leads (eg, Mason -Likar) is not 
recommended given the potential risk of discrepancies with ECGs acquired using standard 
limb lead placement. All scheduled ECGs should be performed after the participant has 
rested quietly for at least 10 minutes in a supine position. 
To ensure safet y of the participants, a qualified individual at the investigator site will make 
comparisons to 
screening measur ements.  Additional ECG monitoring will occur if 
a)apostdose QTc Finterval is increased by  ≥60 msec from the screening andis >450 msec ; 
or b) an absolute QTcF value is ≥500 msec for any  scheduled ECG.  If either of these 
conditions occurs, then 2additional ECGs will be collected approximately  2to 4minutes 
apart to confirm the original measurement.   If the QTc F values from these repeated ECGs 
remain above the threshold value, then a single ECG must be repeated at least hourl y until 
QTcFvalues from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 69If a) a postdose QTcF interval remains ≥30 msec from the screening andis >450 msec; or 
b)an absolute QTcF value is ≥500 msec for an y scheduled ECG for greater th an 4 hours (or 
sooner , at the discretion of the investigator); or c) QTcFintervals get progressively longer, 
the participant should undergo continuous ECG monitoring .  A cardiologist should be 
consulted if QTc intervals do not return to less than the crit erion listed above after 8 hours of 
monitoring (or sooner ,at the discretion of the investigator). 
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important th at leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read 
QTcFvalue is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider ’s interpretation determine s that the QTc values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the S
oAfor 
the timing and frequency. All protocol -required laboratory  assessments, as defined in 
Appendix 2 , must be con ducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues
.  
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study
 in the AE section of the CRF.
Clinically  significant abnormal laboratory  findings are those which are not assoc iated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [
28-35 day s] after the last dose of study  intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/baseli ne within a period of time judged reasonable by  
the investigator, the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -
up assessments in the event of potential 
drug-induced liver injury.
Participant s may  undergo random urine drug testing at the discretion of the investigator.  
Drug testing conducted prior to dosing must be negative for participant s to receive study  
intervention . 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 708.2.5. COVID -19 S pecific Assessments
Participants will be tested for SARS -CoV -
2infection by  PCR prior to being admitted to the 
clinic for confinement and a subsequent SARS -CoV -2test will be performed after 4 days 
(ie,upon completion of 4 x 24 hours in house), or if they  develop symptoms su ggestive of 
COVID -19. 
Additional testing may  be required by  local regulations or by  the Principal Investigator.
Results must be negative for admission to the CRU. 
8.2.6. Management of Hypoglycemia
While hy poglycemia is not expected in the study  participants, fa sting blood glucose will be 
measured as part of laboratory  assessment per the SoA.  In addition, as a precaution, 
participants will be monitored for the signs and s ymptoms associated with hypogl ycemia. 
Any episode of hy poglycemia mu st be captured on the HAE CRF with specific details 
captured on the HAE Form CRF.  For the definition of a h ypogl ycemic episode and severity 
categorization see Section 8.2.6.1 below.
For medical management of hy poglycemia, the investigator may  administer oral 
carboh ydrate, glucagon, or IV glucose according to his or her medical judgment.  At a 
minimum however, treatment or administration of a scheduled meal should be given if 
glucose falls <60 mg/dL for at least 15 minutes, irrespective of whether the study  participant 
exhibits sy mptoms.  I nvestigators may  choose to administer treatment sooner if subjects have 
bothersome s ymptoms of hy poglycemia along with glucose values of ≤ 70 mg/dL.
8.2.6.1. Definition and Severity of Categorization of Hypoglycemic Adverse Event 
(HAE)
The investigator must assess the glucose values reported by  the central/local laboratory , as 
well as an y signs or 
symptoms reported b y the study  participant .
HAE is defined as oneof the following:33
a.Asymptomatic hy poglycemia: An event not accompanied by  typical symptoms of 
HAE but a glucose value of <70 mg/dL  (3.9 mmol/L ) using either glucometer 
(fingerstick blood glucose) at the stud y site or sponsor -identified central/local 
laboratory  (blood glucose).
b.Documented s ymptomatic hy poglycemia: An event during which t ypical s ymptoms 
of HAE are accompanied with a glucose value of <70 mg/dL (3.9 mmol/L), using 
glucometer at the stud y site or sponsor identified central/local laboratory , and the 
clinical picture includes prompt resolution with food intake, subcutaneous glucagon, 
or IV glucose.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 71c.Probable sy mptomatic hypogl ycemia: An event during which sy mptoms of HAE are 
not accompanied b y a glucose determination but was presumabl y caused by a glucose 
concentration of <70 mg/dL  (3.9 mmol/L), and the clinical picture includes prompt 
resolution with food intake, subcutaneous glucagon, or IV glucose.
Each episode of HAE must be categorized with respect to severit y.  In order to characterize 
the event as severe, all 3 criteria below must be met:
1. The participant was unable to treat him/her self.  Neurologic impairment, and not the 
age of the participant, is the explanation for wh y the participant could not treat 
him/herself and required the assistance of another person.
2.The participant exhibited at least 1 of the following neurological symptoms:
Memory  loss.
Confusion.
Uncontrolled behavior.
Irrational behavior.
Unusual difficulty  in awakening.
Suspected seizure.
Seizure.
Loss of consciousness.
3.Either :
If blood glucose was measured and was ≤
54 mg/dL (2.7 mmol/L) using 
glucometer (or central/local laboratory ) or
If blood glucose was not measured, the clinical manifestations were reversed by  
oral carboh ydrates, subcutaneous glucagon, or IV glucose.
Events that do not meet all the criteria above for severe HAE are characterized as mild or 
moderate in severity .
8.2.7. Glucometer Monitoring of Glucose
Monitoring of FSBG using glucometer measurements is not required per protocol, but may  
be obtained if the investigator or participant notes sy mptoms of hy pogly cemia.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 72If obtained, FSBG readings will be ma intained at the CRU in source documents, and only  the 
glucose results from the laboratory  will be reported in the study  database.
If an FSBG result is ≤70 mg/dL, a second FSBG should be obtained to confirm the glucose 
value, in addition to a venous sample that will be sent to the clinical laboratory  for 
confirmation.  If the value from this second FSBG is also 
≤70 mg/dL , the second value will 
be recorded as a h ypogl ycemic AE.  FSBG will continue to be monitored until the glucose 
value returns to >70 mg/dL . Samples may  be taken more frequentl y if deemed necessary  by 
the investigator.  
8.2.8. Pregnancy Testing 
Part A
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the tim es listed in the SoA.  
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy  test result will be required at the baseline visit 
prior the participant’s receiving the stud y intervention/study  treatment. Pregnancy  tests will 
also be done whenever 1 menstrual cy cle is missed during the active treatmen t period (or 
when potential pregnancy is otherwise suspected) and at the end of the study . Pregnancy  
tests may  also be repeated if requested b y IRBs/ECs or if required b y local regulations. 
Part B
Not applicable.
8.2.9. Suicidal Ideation and Behavior Risk Monitoring 
8.2.9.1. Columbia Suicide Severity Rating Scale (C -SSRS)
The C -SSRS is an interview based rating scale to sy stematically  assess suicidal ideation and 
suicidal behavior.27  The “baseline/ screening ” version of the C -SSRS will be administered at 
Screening and Day  -1 in study .  Participants who respond “y es” to Question 4 or 
5(indicating suicidal ideation), or to any suicidal behavioral question on the C-SSRS at 
screening or Day -1 will not be permitted in the study  (see Section 5.2).  The “since last visit” 
version of the C -SSRS will be administered a t the time points specified in the SoA.  The 
C
-SSRS will be administered b y stud y site staff who ha ve completed training in its 
administration.
8.2.9.1.1. Rater Qualifications
For specific rating assessments, only  qualified raters will be allowed to evaluate and/or rate 
participants in this study .  The minimum qualifications a rater must meet for each stud y 
rating assessment will be outlined in the guidance document provided to each participating 
site.  The level of experience with the target population (or equivalent), specific scale 
experience (or equivalent), and certification required (if applicable) will be li sted and used to 
determine whether a rater is approved for a given assessment.  The rater must become 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 73certified to perform selected study  assessments before he or she can participate in the conduct 
of the study .  For specifically  defined assessments, rater training and standardization 
exercises may  be conducted, and written and signed documentation will be provided by  the 
site for each rater’s certification.  In return, each site will be provided written and signed 
documentation outlining each rater’s certi fication for specific study  assessments.  
Recertification may  be required at periodic intervals during the study .  The raters who 
administer specific stud y assessments will be documented in a centralized location and all 
site staff who administer ratings w ill be verified in the site study  documentation during the 
conduct of the stud y.
8.2.9.2. Patient Health Questionnaire -9 (PHQ -9)
The PHQ -9 is a 9 item self -report scale for the assessment of depressive s ymptoms.28  The 
PHQ -9 will be completed by  participants and reviewed b y site staff at the pre -defined time 
points outlined in the SoA.  A PHQ
-9 score of ≥15 at Screening or Day -1 indicates clinicall y 
significant depression and serves as an exclusion criterion for this stud y (see Section
5.2).
8.2.9.3. Referral to a 
MHP
A participant should be referred to a MHP for the following reasons:
Response of “y es” to question 4 or 5, or on an y suicidal behavioral question on the 
C-SSRS .
A score of ≥15 on the PHQ -9.
In the investigator’s judgment a risk assessment or exclusion is required.
A clinically -qualified MHP is a MHP with appropriate training in the assessment of suicide 
risk, according to local clinical practice standards and regulations, who would normally  
evaluate the risk for suicidal ideation and behavior in a patient.
Participants who have recurrent suicidal ideation or behavior during the study  should be 
discontinued from the study  and treated appropriately .If a stud y participant endorses a 4 or 
5 on the ideation subscale or an y behavioral item of the C- SSRS on 2 ormore occasions and 
is confirmed to have active suicidal ideation or behavior on both occasions by  a risk
assessment conducted b y a qualified MHP, then the participant should be discontinued from 
the study  and treated appropriatel y.
Participants who meet c riteria for referral to a MHP, but refuse evaluation and/or treatment 
by a MHP, must be assessed by  the investigator to determine if the participant should be 
discontinued from dosing or from the stud y. 
8.3.Adverse Events ,Serious Adverse Events , and Other Sa
fety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 74AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification a s an SAE or caused the participant to discontinue 
thestudy  intervention (see Section 7.1). 
During the active collection period as described in Section 8.3.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollec ting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s part icipation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of 28 calendar days , except as indicated below, after the last administration of the 
study  intervention .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.
For participants who are screen failures, the active collection perio d ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporaril y discontinues study intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE s after the 
participant has concluded study  participation. However, if the investigator learns of an y 
SAE, including a death, at any
 time after a participant has completed the study , and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to Pfizer using the CT SAE Report Form.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 758.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety  on the CT SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant durin g the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
Reporting of AEs and SAEs for participants who fail screening are subject to the CRF 
requirements as described in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing cau sality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determinat ion of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 76The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRB s/ECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact with or exposure to the study  intervention. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons a t risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such e xposure to 
the study  intervention under study  are reportable to Pfizer Safet y 
within 24 hours of investigator awareness.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. 
Below are examples of 
environmental EDP : 
A female family  member or healthcare provider reports that she is preg nant after 
having been exposed to the study  intervention by  ingestion .
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 77If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until 28daysafter 
the last dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a cop y of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate c an be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
prepro cedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intra uterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnan cy outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infa nt deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  the sponsor. Further 
follow-up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Infor mation 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 788.3.5.2. Exposure During Breastfeeding
An exposure during breas tfeeding occurs if: 
A female is found to be breastfeeding while being exposed or having been exposed to study  
intervention (ie, environmental exposure). An example of environmental exposure during 
breastfeeding is a female family  member or healthcare pro vider who reports that she is 
breastfeeding after having been exposed to the study  intervention by  ingestion .  
The investigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure informatio n does 
not pertain to the participant enrolled in the stud y, so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not create d when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure d uring breastfeeding.
8.3.5.3. Occupational Exposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 
24
hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether there is an associated SAE. 
Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable .
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable .
8.3.8. Adverse Events of Special Interest
Not applicable.
8.3.8.1. Lack of Efficacy
Not applicable.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 798.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the study  interventi onunder stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are rec orded on 
theAE page of the 
CRF. 
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4.Pharmacokinetics 
Blood samples will be collected for measurement of plasma concentrations of atorvastatin , 
ortho- hydroxy atorvastatin, midazolam, 1- OH-midazolam, LE, EE and PF -06882961 as
specified in the SoA.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 80The actual times may  change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of 
samples up to and including 10hours after dose administration that ar eobtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 -minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF.  Collection of samples more than 10 hours after dose
administration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF. This protocol deviation window does not apply  to 
samples to be collected more than 10 hours after dose administration at outpatient/follow-up 
visits with visit windows.
Samples collected for analy ses of study  intervention concentration may  also be use d to 
evaluate safet y or efficacy aspects related to concerns arising during or after the study, for 
metabolite identification and/or evaluation of the bioanaly tical method, or for other internal 
exploratory  purposes.
Samples collected for measurement of pl asma concentrations of study  intervention will be 
analyzed using a validated anal ytical method in compliance with applicable SOPs.  Potential 
metabolites may  be anal yzed with either validated or exploratory methods.
Genetic anal yses will not be performed o n these samples unless consent for this was included 
in the informed consent.  Participant confidentiality will be maintained.
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor.  
On a case -by-
case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised. Any deviation from the specified sample handling 
procedure resulted in compromised sample integrity , will be considered a protocol deviation.
Any changes in the timi ng or addition of time points for an y planned stud y assessments must 
be documented and approved by  the relevant study  team member and then archived in the 
sponsor and site study  files, but will not constitute a protocol amendment.  The I RB/EC will 
be infor med of any  safety  issues that require alteration of the safet y monitoring scheme or 
amendment of the ICD.
8.4.1. PK of Atorvastatin and Ortho- hydroxyatorvastatin
Samples will be used to evaluate the PK of atorvastatin and ortho- hydroxyatorvastatin
(primary  metabolite) .  Blood samples of approximately  4 mL , to provide plasma volume of 
approximately 2 mL , will be collected into appropriately  labeled tubes containing K 2EDTA 
for measurement of plasma concentrations of atorvastatin and ortho- hydroxy atorvastatin as 
specified in the SoA.  Instructions for the collection and handling of biological samples will 
be provided in the laboratory  manual or by  the sponsor.  The actual date and time (24 -hour 
clock time) of each sample will be recorded.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 81Samples collected for analy ses of atorvastatin (plasma) and ortho -hydroxyatorvastatin 
concentration may  also be used to evaluate safety  aspects related to concerns arising during 
or after the study , for metabolite identification and/or evaluation of the bioanaly tical method, 
or for other internal exploratory  purposes.
8.4.2. PK of Midazolam and 1 -OH-Midazolam
Samples will be used to evaluate the PK of midazolam and 1 -OH-m idazolam.  Blood 
samples of approximately 4 mL, to provide two aliquots of plasma volume of approximately
1mL each, will be collected into appropriatel y labeled tubes containing K 2EDTA for 
measurement of plasma concentrations of midazolam and 1 -OH-midazolam as specified in 
the SoA .  Instructions for the collection and handling of biological samples will be provided 
in the laboratory  manual or by  the sponsor.  The actual date and time (24 hour clock time) of 
each sample will be recorded.
Samples collected for analy ses of m idazolam and 1 -OH-m idazolam (plasma) concentration 
may also be used to evaluate safety  aspects related to concerns arising during or after the 
study , for metabolite identification and/or evaluation of the bioanal ytical method, or for other 
internal exploratory  purposes.
8.4.3. PK of Levonorgestrel
Samples will be used to evaluate the PK of LE.  Blood samples of approximately  6mL, to 
provide 
plasma volume of approximately 3mL, will be collected into appropriately labeled 
tubes containing K 2EDTA for measurement of plasma concentrations of LEas spec ified in 
the SoA .  Instructions for the collection and handling of biological samples will be provided 
in the laboratory  manual or by  the sponsor.  The actual date and time (24 -hour clock time) of 
each sample will be recorded.
Samples collected for analy ses of LE plasma concentration may  also be used to evaluate 
safet y aspects related to concerns arising during or after the stud y, for metabolite 
identification and/or evaluation of the bioanal ytical method, or for other internal exploratory  
purposes.
8.4.4. PK of Ethinyl Estradiol
Samples will be used to evaluate the PK of EE.  Blood samples of approximately  6 mL, to 
provide plasma volume of approximately 3mL, will be collected into appropriately labeled 
tubes containing K 2EDTA for mea surement of plasma concentrations of EEas specified in 
the SoA .  Instructions for the collection and handling of biological samples will be provided 
in the laboratory  manual or by  the sponsor.  The actual date and time (24 hour cloc k time) of 
each sample will be recorded.
Samples collected for analy ses of EEplasma concentration may  also be used to evaluate 
safet y aspects related to concerns arising during or after the stud y, for metabolite 
identification and/or evaluation of the bi oanal ytical method, or for other internal exploratory  
purposes.

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 828.4.5. PK of PF-06882961 
Samples will be used to evaluate the PK of PF-06882961.  Blood samples of approximately 
2 mL, to provide plasma volume of approximately 1 mL , will be collected into appropriately labeled tubes containing K
2EDTA for measurement of plasma concentrations of 
PF-06882961 as specified in the SoA.  Instructions for the collection and handling of 
biological samples will be provided in the laboratory manual or by the sponsor.  The actual date and time (24-hour clock time) of each sample will be recorded.
Samples collected for analyses of PF-06882961 plasma concentration may also be used to 
evaluate safety aspects or efficacy related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for other internal exploratory purposes.
 
 
 
 
 
 
 CCI
PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 83 
  
 
 
 
8.6.5. Plasma for Analysis of 4- β-hydroxycholesterol/cholesterol (Part A only)
Blood samples of approximately 4 mL, to provide plasma volume of approximately 2 mL, 
will be collected into appropriately labeled tubes containing lithium heparin for the analysis 
of 4-β-hydroxycholesterol and cholesterol at times specified in the SoA.  Instructions for the 
collection and handling of biological samples will be provided in the laboratory manual.
Samples collected for analyses of 4- β-hydroxycholes terol/cholesterol plasma concentration 
may also be used to evaluate safety aspects or efficacy related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for other internal exploratory purposes.
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a SAP, which will be maintained by the sponsor. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 849.1.Statistical Hypotheses
No formal statistical h ypothesis testing will be performed in this study .
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Enrolled /Randomly  
assigned to stud y 
intervention"Enrolled" means a participant's agreement to participate in a 
clinical study  following completion of the informed consent 
process. Potential participants who are screened for the 
purpose of determining eligibility  for the stud y, but do not 
participate in the stud y, are not considered en rolled, unless 
otherwise specified b y the protocol.
Evaluable All participants assigned to study  intervention and who take 
atleast 1 dose of stud y intervention.
Safety All participants randomly  assigned to study  intervention and 
who take at least 1 dose of study  intervention .
PK Concentration Set The PK concentration population is defined as all participants 
who received at least 1 dose of atorvastatin ,midazolam ,an 
oral contraceptive a nd/or PF -06882961 and in whom at least
1plasma concentration value is reported.
PK Parameter Set The PK parameter anal ysis population is defined as all 
participants who received at least 1 dose of atorvastatin ,
midazolam, an oral contraceptive and/or PF -06882961 and 
have at least 1 of the PK parameters of interest calculated. 
Should vomiting occur after co -administration of atorvastatin , 
midazolam, or the oral contraceptive with PF -06882961, the 
resulting PK parameters from that participant fro m the 
corresponding period may  be excluded, where further details 
will be provided in the SAP .
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. General Considerations
9.3.1.1. Derivation of Pharmacokinetic Parameters
The plasma PK parameters for atorvastatin, ortho- hydroxyatorvastatin, midazolam,
1-OH-midazolam, LE and EEfollowing SD administration (either alone or in 
co-administration with PF -06882961) will be derived from the concentration- time profiles as 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 85detailed in Table 11 below .  The plasma PK parameters for PF - 06882961 following MD
administration will be derived from the concentration- time profiles as detailed in Table 12
below. 
Actual PK sampling times will be used in the derivation of PK parameters. In the case that 
actual PK sampling times are not available, nominal PK sampling time will be used in the 
derivation of PK parameters.
Table 11. Plasma PK Parameters for A torvastatin, Ortho -hydroxyatorvastatin, 
Midazolam, 1-OH- Midazolam, Levonorgestrel and E thinyl Estradiol
Param eter Definition Method of Determ ination
AUC last Area under the plasma
concentration -time profile from 
time zero to the time of the last 
quantifiable concentration (C last).Linear/Log trapezoidal method.
AUC inf* Area under the plasma 
concentration -time profile from 
time zero extrapolated to infinite 
time.AUC last+ (C last*/kel), where C last* is 
the predicted plasma concentration 
at the last quantifiable time point 
estimated from the log -linear 
regression analysis.
Cmax Maximum plasma concentration. Observed directly from data.
Tmax Time for C max. Observed directly from data as time 
of first occurrence.
t1/2* Term inal half -life. Log e(2)/k el,
where k elis the terminal phase rate 
constant calculated by a linear 
regression of the log -linear 
concentration -time curve. Only 
those data points judged to describe 
the terminal log-linear decline w ill 
be used in the regression.
CL/F* Apparent oral clearance. Dose/AUC inf.
Vz/F* Apparent volume of distribution. Dose/(AUC inf • kel). 
Ortho -
hydroxyatorvastatin/atorvastatin 
ratioAtorvastatin metabolite/parent 
ratioOrtho -hydroxyatorvastatin 
AUC/atorvastatin AUC
1-OH-midazolam/midazolam 
ratioMidazolam metabolite/parent 
ratio1-OH-midazolam AUC/midazolam 
AUC
* as data permit ; CL/F and Vz/Fwill not be calculated for ortho -hydroxyatorvastatin or 1 -OH-midazolam .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 86Table 12. Plasma PK Parameters for PF-06882961
Param eter Definition Method of Determ ination
AUC 24 Area under the plasma 
concentration -time profile from 
time zero to time 24 hours .AUC τ1(area under the plasma 
concentration -time profile where 
τ1= 0 to 10 hours) +AUC τ2(area 
under the plasma 
concentration -time profile where 
τ2= 10 to 24 hours) .
Cmax Maximum plasma concentration 
observed from time zero to 
10hours .Observed directly from data.
Tmax Time for C max. Observed directly from data as time 
of first occurrence.
9.3.2. Statistical Methods for Pharmacokinetic Data
The PK data for atorvastatin, ortho- hydroxy atorvastatin, midazolam, 1-OH-midazolam ,LE, 
EEand PF- 06882961 will be anal yzed and reported separately .
Plasma concentrations will be listed and summarized descriptivel y by PK sampling time and 
treatment (dosing alone vs. co- administration or dose by Part of study , as applicable) .
Individual participant and median profiles of the concentration -time data willbeplotted by
treatment. For summary statistics and median plots by sampling time, the nominal PK
sampling time willbeused, forindividual participant plots by time, the actual PK sampling
time will be used for plasma samples. Median profiles will be presented on both linear -linear 
and log -linear scales.
Natural log e-transformed AUC inf(as data permit) of atorvastatin administered alone or 
co-
administered with PF- 06882961 will be anal yzed using a mixed effect model with 
treatment as a fixed effect and participant as a random effect.  Estimates of the adjusted mean 
differences (Test -reference) and corresponding 90% CIswill be obtained from the models.  
The adjusted mean differences and 90% CIsfor the differences will be exponentiated to 
provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIsfor 
the ratios.  The 2 test treatments will be ‘atorvastatin and PF -06882961 120 mg BID’ (Period 
4) and ‘atorvastatin and PF-06882961 200 mg BID’ (Period 7), which will be reported 
separately  in comparison to the reference treatment of ‘atorvastatin alone’ (Period 1).  The 
same anal ysis for natural log e-transformed Cmaxand AUC lastof atorvastatin will also be 
conducted.
Natural log e-transformed AUC inf(as data permit), C maxand AUC lastof midazolam 
administered alone or co -
administered with PF- 06882961 will be anal yzed and reported 
separately  using the same mixed effect model as described above for atorvastatin.  The 2 test 
treatments will be ‘midazolam and PF
-06882961 120 mg BID’ (Period 5) and ‘midazolam 
and PF- 06882961 200 mg BID’ (Period 8), which will be reported separately  in comparison 
to the reference treatment of ‘midazolam alone’ (Period 2).

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 87Natural log e-transfor med AUC inf(as data permit), C maxand AUC lastof LE and EE
administered alone or co -administered with PF- 06882961 will be anal yzed and reported 
separately  using the same mixed effect model as described above for atorvastatin.  For LE, 
the 2 test treatments will be ‘ LE and PF -06882961 120 mg BID’ (Period 3) and ‘ LE and 
PF-06882961 200 mgBID’ (Period 5), which will be reported separatel y in comparison to 
the reference treatment of ‘ LE alone’ (Period 1). Similarly  for EE, the 2  test treatments will 
be ‘EEand PF -06882961 120 mg BID’ (Period 3) and ‘ EEand PF- 06882961 200 mg BID’ 
(Period 5), which will be reported separatel y in comparison to the reference treatment of ‘ EE
alone’ (Period 1).
In the event that less than 12 participants have PK parameters re lated to co -administration 
with PF -06882961 200 mg BID, the above mixed effect models may  
additionally /alternatively include PK parameters from the maximum tolerated dose of 
PF-06882961 (if applicable), where further details will be included in the SAP.
The above and other PK parameters for atorvastatin, ortho- hydroxy atorvastatin, midazolam, 
1-OH-midazolam, LE and EE , and PK parameters for PF- 06882961, will be separatel y 
summarized descriptively b y treatment.
The plasma 4 --hydroxycholesterol, cholesterol and EV concentrations will be summarized 
descriptivel y by period (Day 1 in Periods 2, 5, and 8 in Part A only ). Theplasma ratios of
4--hydroxycholesterol/cholesterol will alsobe summarized descriptively by period .  Perce nt 
change forthe 4- -hydroxy cholesterol/cholesterol ratio from baseline (Day 1 Period 2 in 
PartA) will be reported, where further details will be included in the SAP. Exploratory  EV 
data arenot planned to be included in the CSR.
9.3.3. Other 
Safety Analyses
All safet y anal yses will be performed on the s afety population.
AEs, ECGs, 
BP, PR, body weight and safety  laboratory  data will be reviewed and 
summarized on an ongoing basis during the stud y to evaluate the safet y of participant s. Any 
clinical laboratory ,ECG, BP, and PR abnormalities of potential clinical concern will be 
described.  Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical 
history  and phy sical examination and neurological exa mination information, as 
applicable, collected during the course of the study will be considered source data and will 
not be required to be reported, unless otherwise noted.  However, an y untoward findings 
identified on phy sical and/or neurological examina tions conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE. 
Data collected at screening that areused for inclusion/exclusion criteria, such as laboratory  
data, ECGs ,and vital signs ,will be considered source data, and will not be required to be 
reported , unless otherwise noted.  Demographic data collected at screening will be reported.  

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 889.3.3.1. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, HR, QTcF interval, PR interval, 
and QRS complex will be summarized by treatment and time.
The number (%) of participants with maximum postdose QTcF values and maximum 
increases from baseline in the following categories will be tabulated by treatment: 
Safety QTcF Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (msec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
9.3.4. Other Analyse(s)
Tertiary/Exploratory analyses not included in the pharmacokinetic or safety analyses outlined 
above will be documented in the SAP. 
 
9.4. Interim Analyses
No formal interim analysis will be conducted for this study.  As this is an open-label study, 
the sponsor may conduct unblinded reviews of the data during the course of the study for the purpose of safety assessment, facilitating PK modeling, and/or supporting clinical development. 
9.5. Sample Size Determination
A sample size of approximately 16 participants will be enrolled into each part of the study 
separately (for a total of approximately 32 participants), such that approximately 12 evaluable participants complete each part of the study (for a total of approximately 24 participants).  This number of evaluable participants has been selected to provide sufficient precision to detect a 1.25-fold difference in AUC
inffor either atorvastatin, 
midazolam, LE or EE as described below. 
The primary comparisons of interest are as follows:Part A:
•For atorvastatin AUC
inf: 
•The co-administration of atorvastatin and PF-06882961 120 mg BID (Period 4) 
versus atorvastatin alone (Period 1, reference treatment).CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 89The co -administration of atorvastatin and PF- 06882961 200 mg BID (Period 7) 
versus atorvastatin alone (Period 1, reference treatment) .
For midazolam AUC inf:
The co -administration of midazolam and PF- 06882961 120 mg BID (Period 5) 
versus midazolam alone (Period 2, reference treatment) .
The co -
administration of midazolam and PF- 06882961 200 mg BID (Period 8) 
versus midazolam alone (Period 2, reference treatme nt).
Part B:
For LE AUC inf: 
The co -
administration of LE(as an OC) and PF -06882961 120 mg BID (Period 3) 
versus LE alone (Period
1, reference treatment). 
The co -
administration of LE and PF- 06882961 200 mg BID (Period 5) versus LE 
alone (Period 1, reference treatment). 
For EEAUC inf: 
The co -
administration of EE(as an OC) and PF-06882961 120 mg BID (Period 3) 
versus 
EEalone (Period 1, reference treatment). 
The co -
administration of EEand PF- 06882961 200 mg BID (Period 5) versus EE
alone (Period 1, reference treatment). 
The expected widths of the 90% CIswith 80% coverage probability  for these comparisons 
are shown in Table 13for a range of possible effects based on a sample size of 
12participants for Parts A and B separatel y.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 90Table 13. Expected Widths of the 90% CIs (with 80% Coverage Probability) for 
Different Possible Estimated Effects and Parameters of Interest
ParameterEstimated Effect
(Test/Reference)Probable
90% CIProbable
CI Width
AUC inf(Part A: atorvastatin or
midazolam)75% 60 to 94% 34%
100% 80 to 125% 45%
125% 100 to 156% 56%
150% 120 to 187% 67%
200% 160 to 250% 89%
AUC inf(Part B: LE orEE) 75% 64% to 88% 24%
100% 86% to 117% 31%
125% 107% to 146% 39%
150% 128% to 175% 47%
200% 171% to 234% 63%
These estimates are based on an assumed conservative standard deviation of 
0.284 (equivalent to a geometric coefficient of variation of 29%) in log eAUC inffor both 
atorvastatin and midazolam in Part A of the study. ForLE or EE in Part B of the study , these 
estimates are based on an assumed conservative standard deviation of 0.20 (equivalent to a 
geometric coefficient of variation of 20%) in log eAUC inf.  These estimates are based on data 
from previous internal DDI stud ies of atorvastatin, midazolam or an o ral contraceptive of
LE/EE .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 9110. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable p rivacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the sponsor ,submitted to an I RB/EC 
by the investigator, and reviewed and approved by  the IRB/EC before the stu dy is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amend ments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical dev ice research (if applicable), and all other applicable local 
regulations .
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately .  

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 92In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of the ICH GCP guidelines t hat the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certificatio n or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant and answer all questions regarding the study .The 
participant should be given sufficient time and opportunity  to ask question s and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulati ons, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data re lated to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  the 
spon
sor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 93Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant.
Participants who are rescreened are required to sign a new IC D.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password -protected or secured in a locked room to ensure that only  
authorized study  staff have access. The stud y site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study  site will be responsible 
for determining whether a persona l data breach has in fact occurred and, if so, providing 
breach notifications as required by  law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specifi c numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this singl e, participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Committees Structure
10.1.5.1. Data Monitoring Committee 
This study  will not use a DMC. 
10.1.6. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public regi stries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate , balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 94www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventiona l 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by US law.
EudraCT
Pfizer posts clinical trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authoriz ation applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data sharing
Pfizer provides researchers secure access to patient -level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. Pfizer will make data from these trials available 
24months after study  com pletion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, inc luding individuals 
requesting access for commercial/competitive or legal purposes.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 9510.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password -
protected or secured in a locked room to 
prevent access b y unauthorized third parties.
QTL s are predefined parameters that are monitored during the study .Important deviations 
from the QTLs and any remedial actions taken will be summarized in the clinical study  
report.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study completion. It is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processes (eg, risk- based initiatives in operations and quality ,such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management pla nand 
monitoring plan maintained and utilized by  the sponsor or designee.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the writte n approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 96The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notifica tion in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copies of the inspection findings to the sponsor or i ts agent. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . 
Also, current medical records must be available.
In this stud y, the CRF will serve as the source document. A document must be available at 
the investigative site that identifies those data that will be recorded on the CRF and for which 
the CRF will be the source document.
Definition of what constitutes source data and its origin can be found in the c linical 
monitoring plan , which is maintained by  the sponsor .
Description of the use of the computerized sy stem is documented in the Data Management 
Plan, which is maintained by  the sponsor.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are ac curate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guideli nes, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 97The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon 
study  completion. A study site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  the responsible I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator t o comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is an y conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.10. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts t o the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments , and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards 
concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 98The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study  is documented in the study  contact list located in the SToD system. 
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an ECC at the time of informed 
consent. The ECC contains, at a minimum, (a) protocol and study  intervention identifiers, 
(b) participant’s study  identification number, (c) site emergency  phone number active 
24hours/day , 7 day s per week, and (d) Pfizer Call C enter number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  healthcare 
professionals not involved in the research stud y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The Pfizer Call Cent er number should only  be 
used when the investigator and site staff cannot be reached. The Pfizer Call Center number 
is not intended for use b y the participant directly; if a participant calls that number directl y, 
he or she will be directed back to the in vestigator site.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 9910.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  the clinical laboratory ,or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Table 14. Protocol -Required Safe ty Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
Hematocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN 
Creatinine
eGFR
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST
ALT
Total bilirubin
Direct bilirubin
Indirect bilirubin
GGT
Alkaline phosphatase
Uric acid
Albumin
Total proteinUrinalysis:
pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte 
esterase
Urobilinogen
Urine bilirubin
MicroscopyaHbA1c
Serum pregnancy test 
(-hCG)b
Lipid panel:
Total cholesterol
Direct LDL -C
HDL -C
Triglycerides
TSH
Free T4
Calcitonin
Amylase
Lipase
Serum TBA
PT/INR/aPTT
SARS -CoV -2test
Urine drug screeningc
Screening only:
FSHd
C-peptide (fasting)
HIV
HepBsAg
HCVAb
HCV RNA
Additional Tests (Needed 
for Hy’s Law)
AST, ALT (repeat)
Total bilirubin (repeat)
Albumin (repeat)
Alkaline phosphatase 
(repeat)
Direct bilirubin
Indirect bilirubin
CK
GGT
PT/INR
Total bile 
acidsAcetaminophen drug 
and/or protein adduct levels
a. Only if urine dipstick is positive for blood, protein, nitrites or leukocyte esterase.
b. Part A Only -Serum -hCG for all WOCBP.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 100c. The minimum requirement for drug screening includes cocaine, THC, opiates/opioids, benzodiazepines, and 
amphetamines (others are site and study specific).  At screening, Period 1 Day -1and at the discretion of the 
investigator.
d. For all female participants to confirm PMstatus only.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical sa fety lab oratory  
measurements at baseline and at all times after dose administration may be retained and 
stored for the duration of the study . Upon completion of the study , these retained safet y 
samples may  be used for the assessment of exploratory  safet y biomarkers or unexpected 
safet y findings . These data will not be included in the CSR
. Samples to be used for this 
purpose will be shipped to either a Pfizer -approved BBS facility  or other designated 
laboratory  and retained for up to 1year following the completion of the study .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 10110.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator. Any abnormal laboratory test 
results that meet any of the conditions below must be recorded as an A E:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant addi tional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration, even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
interventi on or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 102Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’ s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) prese nt 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event 
thathypothetically  might have caused death if it were more severe.
c.Requires inpatient h ospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been admitted (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that w ould not have been appropriate in the phy sician’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in dou bt as to whether “hospitalization” occurred or was necessary , the 
AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 103d.Results in persistent or signif icant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,such as uncomplicated he adache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a Pfizer product of an infectious agent, pathogenic 
or non- pathogenic, is considered serious.  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a P fizer product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations, such as significant 
medical events that may jeopardize the part icipant or may  require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatm ent 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency  or drug abuse.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 10410.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; 
(2)nonserious AEs; and (3)
exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE inform ation is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether o r not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE).**
Environmental or 
occupational exposure to 
the product under stud y 
to a non -participant (not 
involving EDP or EDB).None.  Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to Pfizer 
Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is associated w ith an 
SAE, then the SAE is reported to Pfizer Safety using the CT SAE Report Form. 
** EDB is reported to Pfizer Safety using the CT SAE Report Form which w ould also inclu de details 
of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure are 
reported to Pfizer Safety using the CT SAE Report Form. 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 105When an AE or SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shopping for groceries or clothes, using the telephone, managing money , etc.
Severe: Severe or medically significant but not immediately  life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling, limiting self 
care ADL. Self care ADL refers to bathing, dressing and undressing, feeding self, 
using the toilet, taking medication s, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between study  intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 106A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor .However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opinion of causality  in light of follow -up
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined b y the sponsor . In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  the 
sponsor ,to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 107If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide Pfizer Safet y with a cop y of any 
postmortem findings, including histopathology .
New or updated information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 24 h ours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported S AE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to Pfizer Safety  by telephone.
SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimile is not working , notification by  telephone is 
acceptable with a cop y of the CT SAE Report Form sent b y overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 10810.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male
No contraception methods are required for male participants in this study , as the calculated 
safet y margin is ≥100-fold between the estimated maternal exposure due to seminal transfer 
and the NOAEL for serious manifestations of developmental toxicity  in nonclinical studies.
10.4.2. Female Participant Reproductive Inclusion Criteria
Female Participant Options
Part A
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions 
applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a failure 
rate of <1% per year), preferabl
ywith low user dependency , as described below 
during the intervention period and for at least 28 day safter the last dose of study  
intervention, which corresponds to the time needed to eliminate any  reproductive 
safet y risk of the stud y intervention(s).  The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to the first dose of study  
intervention.
Is a WOCBP and using a contraceptive method that is highly  effecti ve (with a failure 
rate of <1% per year), with high user dependency, as described below during the 
intervention period and for at least 28 day safter the last dose of study  intervention, 
which corresponds to the time needed to eliminate any  reproductive sa fety risk of the 
study  intervention(s).  In addition, a second effective method of contraception, as 
described below, must be used.  The investigator should evaluate the effectiveness of 
the contraceptive method in relationship to the first dose of study  intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
Part B
A female participant is eligible to particip ate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 109The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy .
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
beconfirmed before the first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following: 
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview.   The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female.
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  I n addition, a
High FSH level in the postmenopausal range must be used to confirm a 
postmenopa usal state in women under 60 years old and not using hormonal 
contraception or HRT. 
10.4.4. Contracepti onMethods
Part A
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 110Highly Effective Methods That Have Low User Dependency 
1.Intrauterine device.
2.Bilateral tubal occlusion.
3.Vasectomized partner.
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed.  If not, an additional highl y effective method of contraception 
should be used.  The spermatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent 
Sexual abstinence.
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.  The reliability  of sexual abstine nce needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifest yle of the 
participant.
One of the following effective barrier methods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide.
Cervical cap, diaphragm, or sponge with spermicide.
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
Part B
Not Applicable . 

PF-06882961 
Protocol C3421047Final Protocol, 30 August 2021
PFIZER CONFIDENTIAL
Page 111 
 
 
 
 
 
  
 
 
 
 
 CCI
PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 11210.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments
Potential Cases of Dru g-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” 
In some participant s, tra nsaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.  
Participant s who experience a transaminase e levation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in 
TBili ty pically  occurs while 
AST/AL T is/are still elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample). In rare instances, b y the time TBili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing cond itions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 × ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is sm aller).

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 113Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory  tests, detailed history , and physical assessment.  
In addition to repeating measurements of AST and AL T and TBili for suspected Hy ’s law 
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, TBA , and alkaline phosphatase. Consideration should also be given to 
drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiolog y. A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testi ng for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s
for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting th e laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 11410.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus brad ycardia (rate <40 bpm) lasting minutes .
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or b y ≥60 msec from baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: 
ie,rate<120 bpm .
New -
onset t ype I second -degree (Wenckebach) AV block of >30 seconds’
duration.
Frequent PVCs, triplets ,or short intervals (<30 seconds) of consecutive ventricular 
complexes.
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 msec).
New -onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below t he AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with 1 or more pauses of at least 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s uprave ntricular tachycardia (rate >120 bpm) ( “sustained ”= short 
duration with relevant s ymptoms or lasting >1 minute) .

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 115Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm ( heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR > 40bpm to <100 bpm),and 
monomorphic/poly morphic ventricular tachycardia (HR >100 bpm (such as
torsades de pointes) ).
Type II second -degree (Mobitz II) AV block.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion
.
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommen ded as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and Pfizer study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 11610.8. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
Abs absolute
ADL activities of daily living
ADME absorption, distribution, metabolism, and excretion
AE adverse event
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC inf area under the plasma concentration -time profile from 
time zero extrapolated to infinite time
AUC last area under the plasma concentration -time profile from 
time zero to the time of the last quantifiable 
concentration (C last)
AUC τ1 area under the plasma concentration -time profile 
where τ 1= 0 to 10 hours
AUC τ2 area under the plasma concentration -time profile 
where τ 1= 10 to 24 hours
AUC 24 area under the plasma concentration -time profile from 
time zero to time 24 hours
AV atrioventricular
BBS Biospecimen Banking S ystem
BCRP breast cancer resistance protein
-hCG beta-human chorionic gonadotropin
BID twice dail y
BMI body  mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
C-SSRS Columbia Suicide Severity  Rating Scale
cAMP 3’-5’-cyclic adenosine monophosphate 
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical 
Sciences
CK creatine kinase
CKD -EPI Chronic Kidney  Disease Epidemiology  Collaboration
CL/F apparent oral clearance

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 117Abbreviation Term
Clast predicted plasma concentration at the last quantifiable 
time point estimated from the log- linear regression 
analysis
Cmax maximum plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID -19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR Clinical Study Report
CT clinical trial
%CV percent coefficient of variation 
CYP cytochrome P450
DDI drug-drug interaction
DILI drug-induced liver injury
DMC Data Monitoring Committee
EC ethics committee
ECC Emergency  Contact Card
ECG electrocardiogram
eCRF electronic case report form
EDB exposure during breastfeeding
EDP exposure during pregnancy
EE ethiny l estradiol
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
ET early termination
EudraCT European Clinical Trials Database
EV extracellular vesicles
FSBG fingerstick blood glucose
FSH follicle -stimulating hormone
FU follow -up
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma -glutamy l transferase
GLP-1 glucagon -like peptide 1 
GLP-1R glucagon -like peptide 1 receptor 
HAE hypoglycemic adverse event
HbA1c hemoglobin A 1c
HepBsAg hepatitis B surface antigen
HCV hepatitis C virus
HCVAb hepatitis C antibody
HDL -C high densit y lipoprotein cholesterol

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 118Abbreviation Term
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therap y
IB Investigator’s Brochure
IC50 50% inhibitive concentration
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
IMP investigational medicinal product 
IND Investigational New Drug 
INR international normalized ratio
IP investigational product 
IPAL Investigational Product Accountability  Log
IR immediate release
IRB Institutional Review Board
IV intravenous (ly)
IVGTT intravenous glucose tolerance test 
kel first-order elimination rate constant
KI apparent inactivation constant at half-maximal rate of 
inactivation
kinact maximal inactivation rate 
K2EDTA dipotassium ethy lenediaminetetraacetic acid 
LBBB left bundle branch block
LDL -C low density  lipoprotein cholesterol
LE levonorgestrel
LFT liver function test
MATE multidrug and toxin extrusion protein 
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MD multiple -dose
MDR multidrug resistance
MEN2 multiple endocrine neoplasia sy ndrome t ype2 
MHP mental health professional
msec millisecond
MTC medullary  thyroid carcinoma
N/A not applicable
NOAEL no-observed -adverse -effect level
OATP organic anion transporting pol ypeptides
OC oral contraceptive
OCT organic cation transporter 
PCR polymerase chain reaction

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 119Abbreviation Term
PD pharmacod ynamic(s)
PHQ -9 Patient Health Questionnaire -9
PK pharmacokinetic(s)
PM post-menopausal
PR pulse rate
PT prothrombin time
PVC premature ventricular contraction/complex
QD once dail y
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
QTL quality  tolerance limits
Rac mean ratios based on dose normalized AUC 24
RBC red blood cell
SAE serious adverse event
SAP Statistical Analysis Plan
SARS -CoV -2 severe acute respiratory  syndrome coronavirus 2
SD single -dose; standard deviation
SIB Suicidal I deation and Behavior 
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safet y document
SToD study  team on demand
SSID study -specific subject identification number
SUSAR Suspected Unexpected Serious Adverse Reaction
t1/2 terminal half -life
T2DM type 2 diabetes mellitus
T4 thyroxine
TBA total bile acids
TBili total bilirubin
TEAE treatment emergent adverse event 
THC tetrah ydrocannabinol
Tmax time to Cmax
TSH thyroid stimulating hormone
UGT uridine 5' -diphospho glucuronos yltransferase 
ULN upper limit of normal
US United States
USPI United States Package Insert 
Vz/F apparent volume of distribution
WBC white blood cell
WOCBP woman of childbearing potential

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 12011.REFERENCES
1. Ørskov C, Holst JJ, Knuhtsen S,et al. Glucagon -like peptides GLP -1 and GLP -2, 
predicted products of the glucagon gene, are secreted separatel y from pig small intestine 
but not pancreas. Endocrinology .1986;119(4):1467-75.
2. Krey mann B, Williams G, Ghatei MA, et al. Glucagon -like peptide-1 7- 36: a 
physiological incretin in man. Lancet .1987;2(8571):1300
-4.
3. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon -like peptide 1 inhibition of 
gastric empt ying outweighs its insulinotropic effects in healthy  humans. Am J Phy siol.
1997;273(5):E981
-8.
4. Flint A, Raben A, Astrup A, et al. Glucagon -like peptide 1 promotes satiet y and 
suppresses energy  intake in humans. J Clin I nvest .1998;101(3):515 -20.
5. IDF Diabetes Atlas; 9thEdition . Available from: http://www.idf.org/diabetesatlas.
Accessed 04 Feb 2019.
6. Menke A, Casagrande S, Geiss L ,et al. Prevalence of and t rends in diabetes among 
adults in the United States,1988- 2012. JAMA .2015;314(10):1021 -9.
7. Stratton I M, Adler AI, Neil HA, et al. Association of gl ycaemia with macrovascular and 
microvascular complications of ty pe 2 diabetes (UKPDS 35): prospective observational 
study . BMJ .2000;321:405-12.
8. Guh DP, Zhang W, Bansback N, et al. The incidence of co -morbidities related to 
obesity  and overweight: a sy stematic review and meta -analysis. BMC Public Health .
2009;9:88.
9. Flegal KM, Kit BK, Orpana H, et al. Association of all- cause mortality  with overweight 
and obesity  using standard body  mass index categories: a s ystematic review and 
meta -analysis. JAMA .2013;309(1):71 -
82.
10. The GBD 2015 Obesit y Collaborators. Health effects of overweight and obesity  in 
195countries over 25 years. N Engl J Med. 2017;377(1):13 -27.
11. Anderson JW, Konz EC, Frederich RC, et al. Long -term weight -loss maintenance: a 
meta -analysis of US studies. Am J Clin Nutr .2001;74(5):579 -84.
12. Drucker D L.The ascending GLP -1 road from clinical safety  to reduction of 
cardiovascular complications. Diabetes .2018;67:1710 -9. 

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 12113. Lipitor.  Highlights of Prescribing Information. Revised April 2019.  Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020702s073lbl.pdf.
Accessed 24 AUG 2021 Midazolam Hy drochloride Sy rup CIV. August 2015. Available 
from: https://docs.boehringer
-
ingelheim.com/Prescribing%20 Information/PIs/Roxane/Midazolam/MidazolamHClSy r
up.pdf. Accessed 24 AUG 2021.
14. Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg /0.03 mg. United States 
Prescribing Information. Revised May , 2016. Available from:
https://daily med.nlm.nih.gov/dail ymed/fda/fdaDrugXsl.cfm?setid=068199a9 -ef22-
4061-bb76- 1ee58f726018 .Accessed 24 AUG 2021 Brill MJ ,Diepstraten J, van Rongen 
A,et al.  Impact of obesity  on drug metabolism and elimination in adults an d children. 
Clin Pharmacokinet .2012;51(5):277 -304.
15. Aberneth yDR, Greenblatt DJ, Divoll M, et al.  The influence of obesit y on the 
pharmacokinetics of oral alprazolam and triazolam.  ClinPharmacokinet. 1984;9 (2):177-
83.
16. Caraco Y, Zylber-Katz E, Berry  EM, et al. Significant weight reduction in obese 
subjects enhances carbamazepine elimination. Clin Pharmacol Ther. 1992; 51(5) : 501 -
6.
17. Brill,MJ, van Rongen A , van Dongen EP, et al.  The pharmacokinetics of the CYP3A 
substrate 
midazolam in morbidly  obese patient s before and one year after bariatric 
surgery . Pharm Res. 2015;32:3927 –36.
18. Midazolam I njection, USP. United States Prescribing Information.  March 2017. 
Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208878Orig1s000lbl.pdf .
Accessed 24 AUG 2021
19. Greenblatt D J
, Abernethy DR, Locniskar A, et.al. Effect of age, gender, and obesity  on 
midazolam kinetics. Anesthesiology . 1984;61 (1):27-35.
20. GarcíaMJ , Reinoso RF ,Sánchez Navarro A ,etal. Clinical pharmacokinetics of statins. 
Methods Find Exp Clin Pharmacol. 2003: 25(6):457 -81. 
21. Robert LL, Matthy s KE, Verpooten GA, etal. Pharmacokinetics of atorvastatin and its 
metabolites after single and multiple dosing in hypercholesterolaemic haemodialy sis 
patients.  Nephrol Dial Transplant ,
2003:18:967 –76.
22. Posvar EL , Radulovic LL, Cilla DD JR, et.al. Tolerance and pharmacokinetics of 
single -dose atorvastatin, a potent i nhibitor of HMG- coA reductase, in healthy  subjects. J 
Ciin Pharmacol .1996;36:728 -31.
23. Nichols M, Robinson, G, Bounds, W, et al.  Effect of four combined oral contraceptives 
on blood pressure in the pill -free interval. Contraception . 1993; 47:367 -
76.

PF-06882961 
Protocol C3421047
Final Protocol ,30 August 2021
PFIZER CONFIDENTIAL
Page 12224. OZEMPIC®(semaglutide). United States Prescribing Information. January  2020.  
Available from: 
https://www.accessdata.fda.gov/drugsatfda_ docs/label/2020/209637s003lbl.pdf .
Accessed 02 Apr 2020.
25. TRULICITY®(dulaglutide). United States Prescribing Information. February  2020. 
Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf .
Accessed 02 Apr 2020.
26. SAXENDA®(liraglutide ).United States Prescribing Information.
March 20 20.  
Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s011lbl.pdf.
Accessed 02 Apr 2020
.
27. Posner K, Brown GK, Stanley  B, et al. The Columbia -Suicide Severi ty Rating Scale: 
initial validity  and internal consistency  findings from three multisite studies with 
adolescents and adults. Am J Psy chiatry .2011;168(12):1266-77.
28. Kroenke K, Spitzer RL , Williams JB. The PHQ -9: validity  of a brief depression severity
meas ure. J Gen Intern Med .2001;16(9):606 -13.
29. VICTOZA®(liraglutide). United States Prescribing Information. June 2019.  Available 
from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf.
Accessed 02 Apr 2020.
30. Banholzer ML, Wandel C, Barrow P, et al. Clinical trial considerations on male 
contraception and collection of pregnancy  information from female partner: update.  
Clin Transl Med. 2016;5(1):23 -37.
31. University  of Washington, School of Pharmacy , Drug Interaction Solutions.  Available 
from: https://www.druginteractionsolutions.org/ .Accessed 24 AUG 2021
32. Crawford P, Chadwick DJ, Martin C, et al. The interaction of phen ytoin and 
carbamazepine with combined oral contraceptive steroids.  Br J Clin Pharmac. 
1990;30:892 -6.
33. American Diabetes Association. Standards of medical care in diabetes - 2019. Diabetes 
Care .2019;42(Suppl 1): S1- S193.
34. Rodrigues AD, van Dy k M, Sorich MJ, et al. Exploring the use of serum - derived s mall 
extracellular vesicles as l iquid biopsy  to study the induction of hepatic c ytochromes 
P450 and organic anion transporting poly peptides. Clin Pharmacol Ther. 
2021;110(1):248 -58.
